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Abstract 
Microfluidic technology has made a huge impact in the field of biotechnology and 
life sciences. The advancements can be categorized into three aspects: understanding of 
physical phenomena at the microscale; development of tools for easy integration of 
different phenomena; and devising systems for various applications. This thesis highlights 
the ability of microfluidic technology in manipulating different biological entities by 
fabricating small feature sizes. In particular, we have focused on the development of new 
processes for three biotechnology applications – (i) long DNA sample preparation for 
genomic; (ii) delivery of genetic delivery vehicles for gene and cell therapy; and (iii) an in 
vitro model to study human gut. Each of these systems is developed in close collaboration 
with potential users and is aimed towards easy integration with the existing workflow. 
Long-read genomic applications such as genome mapping in nanochannels require 
long DNA that is free of small-DNA impurities. Chapter 2 reports a chip-based system 
based on entropic trapping that can simultaneously concentrate and purify a long DNA 
sample under the alternating application of an externally applied pressure (for sample 
injection) and an electric field (for filtration and concentration). In contrast, short DNA 
tends to pass through the filter owing to its comparatively weak entropic penalty for 
entering the nanoslit. The single-stage prototype developed here, which operates in a 
continuous pulsatile manner, achieves selectivity of up to 3.5 for λ-phage DNA (48.5 
kilobase pairs) compared to a 2 kilobase pair standard based on experimental data for the 
fraction filtered using pure samples of each species. The device is fabricated in fused silica 
using standard clean-room methods, making it compatible for integration with long-read 
genomics technologies.  
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Non-viral delivery vehicles are becoming a popular choice to deliver genetic 
materials for various therapeutic purposes, but they need engineering solution to improve 
and control the delivery process. In Chapter 3, we demonstrate a highly efficient method 
for gene delivery into clinically relevant human cell types, such as induced pluripotent stem 
cells (iPSCs) and fibroblasts, reducing the protocol time by one full day. To preserve cell 
physiology during gene transfer, we designed a microfluidic strategy, which facilitates 
significant gene delivery in short transfection time (<1 minute) for several human cell 
types. This fast, optimized and generally applicable cell transfection method can be used 
for rapid screening of different delivery systems and has significant potential for high-
throughput cell therapy applications. 
Microfluidic in vitro models are being developed to mimic individual or 
combination of various human organ functions for systematic studies, and for better 
predictive models for clinical studies. In Chapter 4, we outline a microfluidic-based culture 
system to study host-pathogen interaction in the human gut. We demonstrate that the 
infection of Enterohemorrhagic Escherichia coli (EHEC) in epithelial cells are oxygen 
dependent and can be used to prolong co-culture of bacterial and epithelial cells. This work 
presents a large scope to study the factors influencing the infection, especially the 
commensal microbiome in the human gut.  
Overall, this thesis shows how the microfluidic system can be useful in solving real-
life problems and envision further advancements in the field of biotechnology.  
  
vi 
 
Table of Contents 
Abstract ............................................................................................................................. iv 
List of Figures ................................................................................................................... ix 
List of Tables .................................................................................................................. xvi 
Statement of the Author’s Contributions ................................................................... xvii 
Chapter 1 – Introduction and motivation ....................................................................... 1 
1.1 The role of microfluidics in biotechnology .............................................................. 1 
1.2 Basic physics of microfluidics .................................................................................. 3 
1.3 Engineering tools for microfluidics .......................................................................... 7 
1.4 Research outline ...................................................................................................... 11 
Chapter 2 – Entropic trap purification of long DNA .................................................. 16 
2.1 Introduction ............................................................................................................. 16 
2.2 Working principle of filtration ................................................................................ 20 
Device design ............................................................................................................ 20 
Concentration of DNA at the microchannel-nanoslit interface ................................ 21 
Separation by sequential injection and filtration steps ............................................. 24 
Tuning the separation performance .......................................................................... 26 
2.3 Material and methods .............................................................................................. 30 
Device Fabrication .................................................................................................... 30 
Sample Preparation ................................................................................................... 32 
Experimental procedure and quantification .............................................................. 32 
Device performance .................................................................................................. 33 
Effect of changing filtration voltage ......................................................................... 37 
vii 
 
Effect of changing filtration time .............................................................................. 40 
2.4 Conclusions ............................................................................................................. 43 
Chapter 3 – Fast, efficient and gentle transfection of human adherent cells in 
suspension ........................................................................................................................ 45 
3.1 Introduction ............................................................................................................. 45 
3.2 Materials and Methods ............................................................................................ 47 
Cell culture ................................................................................................................ 47 
GDV particle preparation .......................................................................................... 48 
Microfluidic device experiment ................................................................................ 49 
Cell surface attachment – Cy5 assay ........................................................................ 52 
Gene expression – GFP assay ................................................................................... 54 
Cell synchronization experiments ............................................................................. 56 
Statistical analysis ..................................................................................................... 57 
3.3 Results and Discussion ........................................................................................... 57 
GDV binding during bulk transfection of adherent cells .......................................... 57 
Gene delivery for the bulk transfection of FugeneHD GDVs .................................. 61 
Cell synchronization to improve gene expression for Glycofect GDVs ................... 64 
Microfluidic-based transfection of cells with GDVs ................................................ 66 
3.4 Conclusion .............................................................................................................. 71 
Chapter 4 – Micro-engineered cell culture systems to study the pathogen-host 
interaction ........................................................................................................................ 74 
4.1 Introduction ............................................................................................................. 74 
4.2 Materials and methods ............................................................................................ 80 
Device Fabrication .................................................................................................... 80 
viii 
 
Cell culture ................................................................................................................ 81 
Bacterial infection on the coverslip .......................................................................... 83 
Bacterial infection on a microfluidic device ............................................................. 83 
Confocal and wide field microscopy ........................................................................ 84 
Oxygen measurement in bulk ................................................................................... 85 
4.3 Result and discussion .............................................................................................. 85 
Epithelial cell layer on the device ............................................................................. 85 
Bacterial virulence in epithelial cells on the coverslip ............................................. 87 
A mathematical model for oxygen consumption for the coverslip setup ................. 88 
Effect of flow rate on EHEC T3SS in epithelial cells .............................................. 92 
4.4 Next generation microfluidic system ...................................................................... 95 
4.5 Conclusion .............................................................................................................. 99 
Chapter 5 – Conclusion and perspective .................................................................... 100 
5.1 Entropic trap purification of long DNA ................................................................ 100 
5.2 Fast, efficient and gentle transfection of human adherent cells in suspension ..... 103 
5.3 Micro-engineered cell culture system as a human gut model ............................... 106 
Chapter 6 – Bibliography ............................................................................................. 109 
 
 
  
ix 
 
List of Figures 
Figure 1.1 a) Microfluidic publications in engineering, multidisciplinary, and biology and 
medicine journals from 2000 to 2012. Figure adapted from Nature.1 b) Time and cost 
estimation for the genome sequencing. Reproduced from Illumina (2018). ...................... 2 
Figure 1.2 Different physical phenomenon prominent in microfluidic systems: a) Laminar 
vs b) turbulent flow regime. The arrow represents the velocity streamlines for two flow 
regimes. c)   Schematic representing the diffusion of small molecules from the high 
concentration region to low concentration region over time. d) Surface and e) interfacial 
tension are the net forces at air-liquid or immiscible liquid-liquid interfaces and are 
dominant at the microscale. ................................................................................................ 6 
Figure 1.3 Size range in a biological system and the relevant length scales used in this 
dissertation using microfluidic systems. ........................................................................... 12 
Figure 2.1 Schematic of the device. The blue regions represent microchannels. The two 
sets of colored nanoslits (gold and grey) represent the main filtration and pre-concentration 
zones discussed in Figure 2.2 and 2.3. The microchannels connecting the nanoslits are 
serpentine channels, seen in more detail in Fig 2.4. ......................................................... 21 
Figure 2.2 Resistor model for the device design in Figure 2.1. a) Potential drop in each slit 
(ΔVi). b) Potential in the top microchannel of Figure 1 at each slit-channel interface (Vi). 
In both cases, the potentials are made dimensionless with the filtration voltage Vf. The six 
nanoslits on either side of purge port 1 are color-coded to indicate the main filtration and 
pre-concentration regions. The DNA recovery channel was not included in the resistor 
model. Note that the y-axis in (b) is plotted in reverse so that maxima in the electric 
potential are more easily interpreted as minima for the DNA electrostatic energy. ......... 23 
Figure 2.3 Dimensions of the microchannel and nanoslit used in the COMSOL model. 
Similar dimensions were used for the resistor model for comparison. There are 12 such 
parallel nanoslits connected by the microchannels as shown in the schematic (Figure 2.1). 
The device was modeled with a 90 nm deep nanoslit and microchannel depth of 1 µm. 24 
Figure 2.4 2D resistor model and 3D COMSOL model showed similar electric potentials 
in the microchannels and nanoslits. a) Plot of the potential drop in each slit for both models.  
b) Plot of the potential at each slit-channel interface in the top channel. The red data 
correspond to the COMSOL model and the black data correspond to the resistor model. 
We observe similar trends in both plots. However, the absolute values are different due to 
the three-dimensional effects that are incorporated into the COMSOL model. The 
COMSOL model focused on the filtration region and did not have the long microchannel 
connecting the ports to the filtration region. To make the comparison between the two 
models, the resistor model was modified from the main text so that it is similar to COMSOL 
x 
 
model dimensions. As a result, the absolute values shown here are different from those of 
Figure 2.2. ......................................................................................................................... 25 
Figure 2.5 Procedure to operate the device. Sequential injection and filtration modes 
correspond to changes in the pressure and voltage at each port. a) Values of the pressure 
and electric potential at each port during a cycle. b) Schematic of the pressure and potential 
profile applied at each port during the two modes of operation.  The pressure shown in the 
figure is the gauge pressure. c) Schematic of a potential use of the device to filter DNA 
mixture of short and long DNA molecules in the two filtration zones (main-filter and pre-
concentration) during the two modes of operation. The pre-concentration zone 
continuously receives DNA from the inlet reservoir. ....................................................... 28 
Figure 2.6 Steps involved in the fabrication of the device............................................... 31 
Figure 2.7 Profilometer data for the a) nanoslit and b) microchannels for the device used 
to produce the separation data in the main text. ................................................................ 32 
Figure 2.8 Validation of device fabrication and operation. a) SEM image of the upper 
microchannel near the center purge port 1 channel (Scale bar 20 µm). b)  SEM image of 
the final slit-channel interface that provides the entropic barrier for filtration (Scale bar 10 
µm). c) Fluorescent image of λ DNA molecules in the main filtration region near the third 
slit just after the completion of the injection cycle. d) Fluorescent image of the λ DNA just 
before the completion of the filtration cycle with the molecules trapped at the slit-channel 
interface. The white lines in (c) and (d) are included to indicate the channel boundaries, 
which are not visible in fluorescence images. .................................................................. 34 
Figure 2.9 Percentage recovery of DNA for the filtration time of 600 s at different filtration 
voltages for a) 2 kbp and b) λ DNA molecules. Each filtration profile is an average of two 
filtration cycles. The color coding is the same for both panels. ....................................... 37 
Figure 2.10 Different trials for the filtration of λ DNA (a-c) and 2 kbp DNA (d-f) at 600 s 
filtration time for various filtration voltages. The final percentage fluorescence intensity of 
these trials are tabulated in Table 2.1................................................................................ 41 
Figure 2.11 a) Percentage recovery of DNA for the filtration voltage of 12 V at different 
filtration times for i) λ DNA and ii) 2kbp DNA molecules. Each filtration profile is an 
average of two filtration cycles. The color coding is the same for both panels. b) Predicted 
selectivity profile for the filtration of λ DNA over the 2kbp DNA. The average fluorescence 
intensity profile for λ DNA and 2 kbp molecules used to obtain the selectivity at a particular 
filtration voltage is the average of three separate trials for λ DNA and two separate trials 
of 2 kbp DNA respectively, shown in Figure 2.10 ........................................................... 42 
xi 
 
Figure 2.12 Data used to compute the percent recovery of DNA for the filtration voltage 
of 14 V at different filtration times for a) 2 kbp and b) λ DNA molecules. Each filtration 
profile is an average of two filtration cycles. .................................................................... 44 
Figure 3.1 Schematic of device fabrication: a) Fabrication of a negative mold of SU8 on a 
silicon wafer; b) Casting of a PDMS replica on the negative mold and bonding of the PDMS 
channel to glass slide using plasma treatment; c) Image of the microfluidic device. ....... 50 
Figure 3.2 Schematic of the experimental setup. Transfection media was filled in a syringe 
and the cell suspension was filled in Tygon® tubing, which is pumped by another syringe 
into the device. The outlet of the device is connected to a flow cytometer for real time-Cy5 
or collected in vial for GFP assay. .................................................................................... 53 
Figure 3.3 Flow cytometry analysis for the transfection of adherent cells (iPSC, HDFn and 
HeLa cells) with FugeneHD in bulk for Cy5 assay. Data are plotted as PI (y-axis) versus 
Cy5 (x-axis). Quadrant 1 (Q1) depicts cells that are only PI positive, Q2 denotes cells that 
are PI and Cy5 positive, and Q3 denotes transfected cells that are only Cy5 positive. All 
experiments were performed in triplicate and analyzed data are plotted in Figure 3.4. ... 58 
Figure 3.4 Comparison of delivery/gene expression (green region) of GDV particles to 
iPSc, HDFn, and HeLa cells in plated cells and in suspension. GDV particles were 
complexes of FugeneHD with pZs-Green plasmids (delivery). Data are reported as the 
percentage of live cells positive for GFP (n = 3). Representative raw flow cytometry data 
with gating are provided in Figures 3.3. [Note: “*” indicates samples are significantly 
different (P<0.05), “NS” indicates no significant differences between samples, all negative 
controls (cell only and pDNA only) < 0.5% and no significant differences between control 
samples for each cell types.] ............................................................................................. 59 
Figure 3.5 Successful binding (pink) of GDV particles (Glycofect complexed with Cy5 
labeled pCM-lacZ) to HDFn and HeLa cells in plated cells and in suspension. Data are 
reported as the percentage of live cells positive for Cy5 (n = 3). [Note: “*” indicates 
samples are significantly different (P<0.05), “NS” indicates no significant differences 
between samples, all negative controls (cell only and pDNA only) <0.5%, and no 
significant differences between control samples for each cell types.] .............................. 60 
Figure 3.6 Flow cytometry analysis for the transfection of adherent cells (iPS, HDFn and 
HeLa cells) with FugeneHD in bulk for GFP assay. Data are plotted as PI (y-axis) versus 
FITC (x-axis). Quadrant 1 (Q1) depicts cells that are only PI positive, Q2 denotes cells that 
are PI and FITC positive, and Q3 denotes transfected cells that are only FITC positive. All 
experiments were performed in triplicate and analyzed data are plotted in Figure 3.7. ... 62 
Figure 3.7 Comparison of delivery/gene expression (green region) of GDV particles to 
iPSc, HDFn, and HeLa cells in plated cells and in suspension. GDV particles were 
complexes of FugeneHD with pZs-Green plasmids (delivery). Data are reported as the 
xii 
 
percentage of live cells positive for GFP (n = 3). Representative raw flow cytometry data 
with gating are provided in Figures 3.6. [Note: “*” indicates samples are significantly 
different (P<0.05), “NS” indicates no significant differences between samples, all negative 
controls (cell only and pDNA only) < 0.5% and no significant differences between control 
samples for each cell types.] ............................................................................................. 63 
Figure 3.8 Flow cytometry analysis for the delivery (GFP assay) of GDV particles 
(Glycofect and pZs-Green) to HDFn cells synchronized at the transition of G1/S phase in 
15 minute transfection time for plated and suspension condition. Data are plotted as PI (y-
axis) versus FITC (x-axis). Quadrant 1 (Q1) depicts cells that are only PI positive, Q2 
denotes cells that are PI and FITC positive, and Q3 denotes transfected cells that are only 
FITC positive. All experiments were performed in triplicate and analyzed data are plotted 
in Figure 3.9. ..................................................................................................................... 64 
Figure 3.9 Successful suspension delivery of GDV particles (Glycofect and pZs-Green) to 
HDFn synchronized at the transition of G1/S phase. The cells were transfected for 15 
minutes, followed by 96 hours of incubation. As a control, a cell monolayer was transfected 
for 15 minutes followed by 72 hours of incubation. Data are reported as the percentage of 
live cells positive for GFP (n = 3) and pictorially represented as green circles in the 
figure. Representative raw flow cytometry data with gating are provided in Figure 3.8. 
[Note: “*” indicates samples are significantly different (P<0.05), all negative controls (cell 
only and pDNA only) <0.5%, and no significant differences between control samples for 
each cell types.] ................................................................................................................. 65 
Figure 3.10 Schematic of the microfluidic suspension transfection device. The figure was 
designed by Nilesh Ingle. .................................................................................................. 66 
Figure 3.11 Mixing profile for total flow rates of 20 (blue), 50 (red), and 110 μL/min 
(green) in the microfluidic device. Water was used instead of the GDV solution and a 
solution of fluorescein was used instead of the cell solution. Ratio of flow rates for water 
and fluorescein solution was 4:1in all cases. Fluorescent images were taken at the inlet 
(solid line) and outlet (dash line) of the device (position marked in device image) and the 
fluorescent intensity was measured using ImageJ software. ............................................ 67 
Figure 3.12 Successful microfluidic binding (pink) of FugeneHD GDVs to HDFn and 
HeLa cells (pCMV-lacZ plasmid).  Flow rates were 10 μL/min (cells) and 40 μL/min 
(GDVs); the effective contact time between cells and GDVs was < 1 minute. Data are 
reported as the percentage of live cells positive for Cy5 (n = 3).  a) Representative raw flow 
cytometry data with gating and b) analyzed result of  the flow cytometry data. [Note: “*” 
indicates samples are significantly different (P<0.05) from “cell only” control, all negative 
controls (cell only and pDNA only) < 0.5%, and no significant differences between control 
samples for each cell types.] ............................................................................................. 68 
xiii 
 
Figure 3.13 Effect of the relative flow rate of the inlet streams on GDV attachment to the 
cell surface for HeLa cells transfected with Glycofect GDV particles formulated with Cy5-
labeled pCMV-lacZ plasmid. a) Representative raw flow cytometry data with gating for 
various flow rates. Data are plotted as PI (y-axis) versus Cy5 (x-axis). Quadrant 1 (Q1) 
depicts cells that are only PI positive, Q2 denotes cells that are PI and Cy5 positive, and 
Q3 denotes transfected cells that are only Cy5 positive. b) Analyzed data for the effect of 
flow rate on GDV attachment on cell surface. [Note: “*” indicates samples are significantly 
different (P<0.05) from “cell only” control, all negative controls (cell only and pDNA only) 
< 0.5% and no significant differences between control samples for each cell types.] ..... 69 
Figure 3.14 Flow cytometry analysis for the delivery (GFP assay) of FugeneHD GDVs to 
PFB, HDFn and HeLa cells using the microfluidic device. Data are plotted as PI (y-axis) 
versus FITC (x-axis). Quadrant 1 (Q1) depicts cells that are only PI positive, Q2 denotes 
cells that are PI and FITC positive, and Q3 denotes transfected cells that are only FITC 
positive. All experiments were performed in triplicate and analyzed data are plotted in 
Figure 3.15. ....................................................................................................................... 70 
Figure 3.15 Successful gene delivery (green) to primary fibroblasts (PFB), HDFn, and 
HeLa cells (pZs-Green plasmid). Flow rates were 10 μL/min (cells) and 40 μL/min 
(GDVs); the effective contact time between cells and GDVs was < 1 minute. Data are 
reported as the percentage of live cells positive for GFP (n = 3). Representative raw flow 
cytometry data with gating are provided in Figures 3.14. [Note: “*” indicates samples are 
significantly different (P<0.05) from “cell only” control, all negative controls (cell only 
and pDNA only) < 0.5%, and no significant differences between control samples for each 
cell types.] ......................................................................................................................... 71 
Figure 3.16 Optimization of delivery parameters for suspension transfection in a 
microfluidic device. Flow cytometry analysis for the transfection of HeLa with FugeneHD 
using a microfluidic device for a) different flow rates and b) different GDV concentration. 
Data are plotted as PI (y-axis) versus FITC (x-axis). All experiments were performed in 
triplicate. c) Effect of total flow rate on gene expression/delivery of GDV particles to HeLa 
cells in suspension with FugeneHD formulated with pZs-Green plasmid. Cell to GDV 
suspension flow rate ratio is 1:4. d) Effect of reagent concentration on gene expression for 
HeLa cells in suspension. GDV is FugeneHD complexed with pZs-Green plasmid with 1X 
concentration (2.64 μg pDNA/ 50,000 cells).  Flow rates were 10 μL/min (cells) and 40 
μL/min (GDVs). [Note: “*” indicates samples are significantly different (P<0.05) from 
“cell only” control, all negative controls (cell only and pDNA only) < 0.5% and no 
significant differences between control samples for each cell types.] .............................. 72 
Figure 4.1 a) Schematic of device with the intended use for cell culture. b) & c) are the 
side and top views of the assembled device respectively, highlighting device components 
and channel dimensions. ................................................................................................... 80 
xiv 
 
Figure 4.2 Workflow for the device fabrication involving photolithography and soft 
lithography process in silicon and PDMS respectively. ................................................... 81 
Figure 4.3 a) The experimental setup for the bacterial infection. The fluid flow in the 
bottom channel was controlled by syringe pump and the bacterial cells are cultured in the 
top channel under quiescent condition. b) Schematic of epithelial and bacterial cells 
locations inside the device during the bacterial infection. ................................................ 84 
Figure 4.4 Confocal image of the epithelial cells in a microfluidic device. The cell nuclei 
were labelled with Hoechst stain (blue) and cell actin were stained with FITC-phalloidin 
(green). a) The confocal image of Caco2 cell along the microfluidic channel  (scale bar 500 
µm) and b) the representative confocal image on the channel for different cell epithelial 
cells: HeLa, HT29 and HT29+Caco2 cells (scale bar 200 µm). ....................................... 86 
Figure 4.5 Representative images of EHEC infection for 6h in a) HeLa and b) HT29 cells 
in the coverslip setup. Images show m-cherry expressing EHEC (red), Hoechst stained 
nuclei (blue) and the FITC immune-stained EspA (green). .............................................. 88 
Figure 4.6 Steady state diffusion in a standing liquid. Concentration of oxygen molecule 
in liquid solution will be established by its diffusive influx through the surface as well as 
in bulk (Jy), while it is continuously consumed (𝑅v)in the bulk liquid. The schematic 
represents the mass balance and the boundary condition for small molecule in bulk. The 
mass balance at a steady state include the diffusion flux at element interface of area A and 
bulk consumption 𝑅v ........................................................................................................ 89 
Figure 4.7 a) Schematic of coverslip setup used for bacterial infection. This setup was used 
to measure the oxygen concentration in media over time, which is similar to the coverslip 
condition. b) Temporal measurement of dissolved oxygen (%) in media using a DO probe 
for 6 h duration.................................................................................................................. 93 
Figure 4.8 Representative image for the EspA expression due to EHEC infection in HT29 
cells at 50 µL/h for the 9 h and 24 h infection. Images show m-cherry expressing EHEC 
(red), Hoechst stained nuclei (blue) and the FITC immune-stained EspA (green). Scale bar 
20 µm. ............................................................................................................................... 95 
Figure 4.9 Representative image for the EspA expression due to EHEC infection for 6 h 
in HeLa cells at different flow rates: a) 50 µL/h and b) 0.5 µL/h. Images show m-cherry 
expressing EHEC (red), Hoechst stained nuclei (blue) and the FITC immune-stained EspA 
(green). Scale bar 20 µm. .................................................................................................. 96 
Figure 4.10 Representative image for the EspA expression due to EHEC infection for 6 h 
in a) Caco2 cells and b) HT29+Caco2 cells at 0.5 µL/h. Images show m-cherry expressing 
EHEC (red), Hoechst stained nuclei (blue) and the FITC immune-stained EspA (green). 
Scale bar is 20 µm. ............................................................................................................ 97 
xv 
 
Figure 4.11 a) Schematic of modified device with the additional control channel. b) 
Schematic of epithelial and bacterial cells location inside the device along with the control 
channel during the bacterial infection. Flow of oxygen-rich media or nitrogen gas will be 
controlled in the top channel depending on the intended role of the new device as a control 
device or anaerobic micro-reactor respectively. ............................................................... 98 
Figure 5.1 Schematic of the proposed dual-stage filtration. The two stages can have 
different slit height depending on the application. .......................................................... 101 
Figure 5.2 The proposed device for incorporating nanochannel with the filtration system 
for genome mapping applications. This device is being fabricated and tested in our group 
by Hui-Min Chuang. ....................................................................................................... 103 
Figure 5.3 Schematic shows the integration of microcarriers and gene delivery for large 
scale manufacturing. It can be further improved by incorporating our protocol and 
microfluidic system. Figure was adapted from Molecular Therapy - Methods and Clinical 
Development.161 .............................................................................................................. 106 
 
  
xvi 
 
List of Tables 
Table 2.1 Percentage recovery of DNA molecules different trials and averaged DNA 
recovery for two DNA types as well as the selectivity of filtration at 600 s filtration time 
for different filtration voltages. Electric field in slit 3 was calculated for each filtration 
voltage using the resistor model shown in Figure 2.2. ..................................................... 39 
Table 2.2 Percent recovery of individual DNA molecules for 600 s and 450 s filtration as 
well as the anticipated recovery at 450 s based on the filtration profile from 600 s filtration 
time. Electric field in slit 3 was calculated for each filtration voltage using the resistor 
model shown in Figure 2.2................................................................................................ 40 
Table 4.1 Parametric calculation for oxygen consumption in coverslip setup. ................ 92 
  
xvii 
 
Statement of the Author’s Contributions 
Portions of this dissertation were written in collaboration with the members of the 
Dorfman, Reineke, Tolar, Hu and Dunny group. Some chapters have also appeared as 
articles in various journals. Here, I would like to point out the contributions of the diﬀerent 
people involved.  
Chapter 2 was published as an article: Pranav Agrawal, Z. Bognár and K. D. 
Dorfman, “Entropic trap purification of long DNA”, Lab Chip, 18, 955 (2018). In this 
paper, we have developed a chip-based system based on entropic trapping that can 
simultaneously concentrate and purify a long DNA sample under the alternating 
application of an applied pressure (for sample injection) and an electric field (for filtration 
and concentration). I performed all experiments and data analysis for the published work. 
The original resistor code was developed by K.D.D and I further modified based on the 
actual device design. I developed the initial COMSOL model and Z.B expanded the model 
to incorporate various device dimension for predicting electric field profile inside the 
device. K.D.D and I wrote most of the paper.  
Chapter 3 appeared as Pranav Agrawal, N. P. Ingle, W. S. Boyle, E. Ward, J. Tolar, 
K. D. Dorfman, and T. M. Reineke, “Fast, Eﬃcient, and Gentle Transfection of Human 
Adherent Cells in Suspension”, ACS Appl. Mater. Interfaces, 8, 8870 (2016). This paper 
demonstrated a highly eﬃcient method for gene delivery into clinically relevant human 
cell types, such as induced pluripotent stem cells (iPSCs) and ﬁbroblasts, reducing the 
protocol time by one full day. The experiments for this paper were conceived, initiated and 
designed by N.P.I, K.D.D, T.M.R and me. J.T provided the PFB cells and iPSCs. I and 
W.S.B. performed iPSC experiments. E.W. trained and advised on iPSCs culture protocol. 
I and N.P.I carried out the rest of the biological experiments and analyzed the results. I 
designed and fabricated the microfluidic device. Experimental conditions and operating 
parameters were optimized by me and N.P.I. The manuscript was written by N.P.I, K.D.D, 
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Chapter 1 – Introduction and motivation 
1.1 The role of microfluidics in biotechnology 
The last two decades have seen major advancements in microfluidic-based 
research, especially in the fields of biotechnology and life science (Figure 1.1a).1 The 
average timeline for a technology development to reach widespread commercialization 
from the lab scale is 29 years.2 In the case of microfluidic, it has already made a huge 
impact as many have reached a commercial stage. The microfluidic market was valued at 
$1.6 billion and is projected to reach $3.5 - 5.8 billion by 2018.3 Some of the popular and 
important applications of these technologies involve targeted diagnostic platforms,4 
analytical tools,5 in vitro models,6 nanoparticle assembly, genomics, and sample 
preparation.7 The term “lab-on-a-chip” has been coined for certain microfluidic 
technologies that miniaturized specific laboratory functions or operations. Several 
laboratory functions have already been translated to the micro- or nanoscale including drug 
and biologics delivery,8 cell- and biochemical-based assays, cell sorting,9 gel 
electrophoresis,10 and various chemical reactions. Initial technology developments 
stemming from engineering laboratories are limited to only a handful of the population, 
mainly due to the requirement of expertise and the high cost of adaptation by a non-
engineering laboratory. The major engineering contribution to the field has been the 
development of scaling laws, based on various physical concepts such as fluid flow and 
surface forces, for device design as well as tools for device fabrications. The first major 
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success in the translation of microfluidic technology for general users is point-of-care 
diagnostic, especially for developing nations. Another important example is genome 
sequencing – the innovative conglomeration of microfluidics, biochemistry, optical and 
electronic techniques have translated a multibillion-dollar project to a $1000 commercial 
product (Figure 1.1b). Most advances were made when the developmental efforts were 
focused on either reducing the total operational cost such as that of genome sequencing or 
achieving functionalities which, otherwise, cannot be easily implemented using existing 
methods such as single cell manipulation. The increasing popularity of the field and 
interdisciplinary collaborations have refined the developmental approach for laboratory 
and commercial applications.  
 
Figure 1.1 a) Microfluidic publications in engineering, multidisciplinary, and biology and 
medicine journals from 2000 to 2012. Figure adapted from Nature.1 b) Time and cost 
estimation for the genome sequencing. Reproduced from Illumina (2018). 
The characteristic advantages of microfluidic technology include low cost and 
design flexibility in fabrication, high-throughput or multiplex systems with process 
automation capabilities, real-time and on-line analysis, and low reagent and sample cost. 
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All these advantages stem from advancements in the fundamental understanding and the 
fabrication tools for the microfluidic applications. The cost, flexibility and multiplexing in 
the microfluidic technology is a direct consequence of advancements in the fabrication 
tools and the material development. The low reagent cost and fast response time are 
attributed to the small length scale involved in this technology which is a direct result of 
the in-depth understanding of the scaling laws at nano- and microscale in addition to the 
fabrication advancements. One example is the microfluid-based assay provides an 
additional advantage of assessing biological response at the single-cell level as compared 
to the large cell population at the macroscale that can have inherent heterogeneity in the 
cell population. In this assay, a minimum cell concentration is necessary to detect the 
biological response; operating at small volumes (nano-litres) will require 1 cell as 
compared to 106 cells when operated at the macroscale (millilitre). Indeed, in these 
examples, it is necessary to have a thorough understanding of the scaling laws and 
fabrication tools relevant to the microfluidic technology. 
1.2 Basic physics of microfluidics 
The physical phenomena and forces dominant at the microscale may be 
significantly different from that observed at the macroscale and this drives some of the 
applications that were not feasible before the advent of microfluidic technology.11 A 
scaling law, determined by a dimensionless number, compares the significance of two 
competing forces or phenomena.  
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A common dimensionless number characterizes the fluid flow is the Reynolds 
Number (𝑅𝑒), which compares the impact of inertial to viscous forces and determines the 
flow profile in the channel. 𝑅𝑒 is given by 
𝜌𝑈0𝐷ℎ
𝜂
, where  𝜌 and  𝜂 are the density and 
viscosity of fluid respectively, while 𝑈0 and 𝐷ℎ represent characteristic fluid velocity and 
channel dimension respectively. 𝑅𝑒 is generally used to predict the flow profile in the 
channel: laminar or turbulent (Figure 1.2a & b). For a fluid, 𝑅𝑒 is proportional to the 
channel dimension. Turbulent flow profile is more prevalent at the macroscale for large 𝑅𝑒 
(>~2300) and is characterized by the time-dependent chaotic flow. For a microfluidic 
system, 𝑅𝑒 typically ranges between 0.1 to 10. The laminar flow in a microchannel is 
dominated by viscous flow and has a time-independent flow profile. Such flow condition 
is either a blessing or a curse depending on the application. For example, the laminar flow 
profile has been used to promote cell sorting. On the other hand, the parallel flow profile 
makes it very difficult to mix two streams and therefore require other methods to assist in 
mixing at the microscale. 
Diffusion is the net movement of small molecules from the region of high 
concentration towards low concentration because of the Brownian motion (Figure 1.2c). 
The distance travelled by a molecule in a one-dimensional system is represented by 𝑑2 =
2𝐷𝑡, where 𝑑 is the distance travelled by a particle with diffusivity 𝐷 over time 𝑡. The 
diffusivity of a particle depends upon its size, and smaller particles diffuse faster compared 
to large particles. At the microscale, diffusion often competes with convective flow. This 
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is represented by the Peclet number(𝑃𝑒 ≡
𝑙𝑈0
𝐷
), which is the ratio between timescales for 
diffusion and convection. The most common application involves the diffusion of 
molecules perpendicular to that of the fluid flow. For example, in the case of mixing of two 
streams in a straight channel, diffusion is the dominant mechanism for the motion of 
molecules between parallel flow fields. A fast response in a microfluidic system is due to 
the rapid transport process, which is a direct result of the high surface area to volume ratios 
(SA/V) in a microfluidic system. Novel device designs have been tested for high SA/V and 
have achieved fast mixing or controlling isothermal conditions for various biological 
processes. For example, efficient temporal and spatial temperature control helps in 
achieving high-quality polymerase chain reaction in different microfluidic systems.12  
 Several other surface forces dominate significantly in microscale systems. For 
example, the capillary phenomenon, which is an interplay between the surface tension of 
the liquid and the surface chemistry and geometry of the channel, is dominant at the 
microscale (Figure 1.2d & e). A popular application of this phenomena at the microscale 
is droplet microfluidics where droplets are generated based on the difference in the 
interfacial tension between two immiscible liquids.13 These droplets are often used as 
micro-reactors to perform biological and chemical processes such as single-cell 
genomics.14 Oil-water systems are commonly used for droplet-based microfluidic systems. 
Capillary number compares the importance of viscous forces with respect to the interfacial 
tension and it represented by 𝐶𝑎 =
𝜂𝑈0
𝛾
, where 𝛾 of the surface tension of a liquid. Another 
popular phenomenon is electro-kinetic transport comprising of electro-osmosis and 
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electrophoresis.15 Electro-osmosis is the motion of the bulk liquid in the presence of an 
external electric field and requires the presence of charge double layer at the solid-liquid 
interface. On the other hand, electrophoresis is the motion of a charged particle in a 
stationary liquid in the presence of an external electric field. The electro-kinetic transport 
Figure 1.2 Different physical phenomenon prominent in microfluidic systems: a) Laminar 
vs b) turbulent flow regime. The arrow represents the velocity streamlines for two flow 
regimes. c)   Schematic representing the diffusion of small molecules from the high 
concentration region to low concentration region over time. d) Surface and e) interfacial 
tension are the net forces at air-liquid or immiscible liquid-liquid interfaces and are 
dominant at the microscale. 
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phenomenon becomes important when the width of the charge double layer becomes 
comparable to the size of the channel or charged molecules. This has been very useful in 
the manipulation of polyelectrolytes such as DNA, protein, as well as, plug-like fluid flow 
without external pressure. For a specific application, the use of appropriate 
phenomenological model (scaling laws) is often dictated by its compatibility with the 
fabrication tool and materials used in the fabrication required for the implementation of the 
model. 
1.3 Engineering tools for microfluidics 
The theoretical understanding of many of the above discussed physical 
phenomenon has been under development for years, but their true potential for the 
microfluidic system was realized due to the advancement in the fabrication tools that 
facilitate the implementation of relevant physical conditions necessary for an application. 
Conventional microfabrication techniques were the early tools adopted for fabricating 
microfluidic devices, which involved the patterning of the desired design in a 
photosensitive polymer (photoresist) and transferring the final pattern to the desired 
material. Silicon and glass are popular material choices for bulk manufacturing using 
microfabrication, in semiconductor and microelectromechanical systems (MEMS) 
industry. The commercial application of microfabrication has streamlined fabrication 
protocols along with sophisticated equipment and advanced materials for various 
applications.16 Despite the advancements in the semiconductor and MEMS industry, the 
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advent of elastomer-based lithography – Polydimethylsiloxane (PDMS) replica molding – 
was the major factor that promoted the widespread use of microfluidic technologies.  
The PDMS-based fabrication, often referred to as the soft lithography, involves the 
fabrication of the silicon mold that usually contains the negative pattern of the design 
intended to be fabricated followed by mold casting with well-mixed PDMS precursors and 
thermal crosslinking for the final pattern.17 The elastomeric nature of PDMS allows easy 
peeling of the casting from the mold as well as the simple punching of access hole for the 
fluidic connections. The elastomeric property is also very crucial for some of the novel 
device designs such as on-chip pumps and valves. In addition to the elastomeric property, 
PDMS is virtually the default material for laboratory microfluidic devices due to its low 
cost, ease of fabrication, good optical property for imaging (transparent to broad 
wavelengths with low autofluorescence of the material), high gas permeability for cell 
culture and biocompatibility. However, PDMS possess some limitations in the casting 
process as well as its use for the microfluidic devices. Commercial PDMS formulation is 
too soft for the fabrication of high aspect ratio features, assist non-specific protein and 
small molecule adsorption on its hydrophobic surface, and is incompatible with common 
organic solvents. High water permeability in PDMS can be challenging to handle, as it can 
introduce bubbles during device operation. Several chemical modifications for PDMS-
based lithography has been explored in the literature to tackle the aforementioned 
limitations, including post-curing surface modification,18 and change in chemical 
formulation.19 In addition, new elastomeric materials have been tested as well as their 
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casting protocols are being standardized for soft lithography. As microfluidic technologies 
advance from the lab scale to the commercial scale, more accessible and cost-effective 
materials such as polymethyl methacrylate,20 cyclic olefin copolymer,21 or polycarbonate22 
are being explored as alternatives that can be fabricated with the variety of the industrial 
techniques including microinjection molding, hot embossing, casting and mechanical or 
laser micromachining.  
Glass and silicon are also popular materials, especially for commercial 
applications.23 There are many applications where both materials provide advantages over 
the polymeric such as precise definitions of nano-scale channels or pores, fabrication of 
high aspect ratio structures, chemical resistivity and ease of electrode integration. The high 
material or equipment cost associated with both materials are often mitigated through bulk 
manufacturing or device reusability. For example, different wafer sizes ranging from 2”–
12” diameter are already available for bulk manufacturing which lowers the development 
cost when it is being adopted for microfluidic-based commercial applications. At the 
laboratory scale, silicon is advantageous for applications that require high thermal 
conductivity, hydrophilic surface and electrode integration. The wet and dry etching 
processes are already standardized for fast and precise small-scale fabrications. Moreover, 
several bonding methods including thermal, anodic and adhesive bonding assist in easy 
integration with different materials.  
For many electro-kinetic applications, silicon dioxide is chemically grown on Si as 
an insulating layer. Glass wafer provides a simple alternative for such applications.24,25 
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Furthermore, it also provides precise feature size with the possibility of high aspect ratio 
structures, transparent material for imaging, high chemical resistance and established 
chemical modifications for tuning the surface hydrophobicity. Fabrication and bonding 
methods similar to those of silicon are also available for glass materials.26 Three types of 
glass materials are popular for such applications – soda lime, borosilicate and quartz. Soda 
lime can achieve fast etching and high bonding strength at a relatively lower temperature, 
but it provides lower etch quality and suffers from high autofluorescence. On the other 
extreme, quartz is the purest form of SiO2 with minimal autofluorescence and background 
noise making it ideal for optical application. However, it has a very slow etch rate for 
fabricating features and requires high temperature for thermal bonding.  
All of the above techniques require a cleanroom facility for part or complete device 
fabrication, which significantly increases the overall fabrication cost and limits the 
potential users. Recent advancements are being made to use rapid prototyping techniques 
like 3D printing for the microfluidic device fabrication. A major motivation comes from 
the development and commercialization of several 3D products with useful resolution and 
accuracy, and some are as cheap as a few thousand dollars.27 A 3D printing approach is 
especially an attractive tool for microfluidic as it supports the designing of complex 
geometry in a three-dimensional space, which otherwise is difficult and expensive to 
fabricate using microfabrication methods. 3D printing for microfluidic devices has been 
successfully implemented for simple and larger geometry (>100 µm). This technology is 
still in a developmental stage – in terms of the desired resolution and accuracy for smaller 
11 
 
length scales as well as a small library of material that can be used with commercial 
systems.28 However, new printing design and materials are being developed both at the 
laboratory and industrial scale that leads to a large number of 3D printing-based devices, 
making it a “next-generation” tool for microfluidic technology.  
1.4 Research outline 
With great advancements in the fundamental understanding and development of 
diverse engineering tools for the microfluidic technology, the field is now well poised for 
its implementation in various biotechnology applications. An important consideration in 
this endeavour is to realize the shortcomings of existing protocols/processes or the need 
for a new method and then devising a simple platform that can be easily integrated into the 
existing workflow. The objective of this dissertation is to advance the existing microfluidic 
technology for novel applications in the field of biotechnology, in particular for the fast 
delivery of genetic materials necessary for cell therapy, efficient sample preparation for 
genomics and a reliable in vitro model to study gut microenvironment. Each of the systems 
presented in this dissertation was built upon the need to improve conventional standards in 
an application and used the conventional methodology for the validation of the new system.  
Figure 1.3 demonstrates the range of length scale in the human body along with the 
relative length scale that is accessible with the microfabrication techniques and has been 
explored in this dissertation. Nucleic acids are fundamental to the existence of living 
species as it constitutes the genetic material of cells in the form of deoxyribonucleic acid 
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(DNA) as well as ribonucleic acid (RNA). The ability to manipulate this genetic material 
is very crucial for the mechanistic understanding of cellular function and disease 
manifestations as well as various biotechnology applications. A DNA is made up of four 
types of nucleotides (or base) ‒ adenine (A), guanine (G), cytosine (C) and thymine (T), 
while for RNA, the fourth nucleotide is uracil (U) instead of thymine. The size of a 
nucleotide is in the order of a few angstroms. However, the assembled nucleic acid may 
range from tens of nanometers to few microns, depending upon its source and usage. For 
example, a human genome is over 3 billion base pairs (bp) while the circular DNA 
(plasmid) for a cell therapy has few thousand base pairs. The size and complexity of the 
genetic materials in a cell depends on the type of cells and organism. Prokaryotic cells are 
simple cells with less genetic information with few cellular functions and small cell size 
 
Figure 1.3 Size range in a biological system and the relevant length scales used in this 
dissertation using microfluidic systems. 
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(few hundred nanometers). On the other hand, eukaryotic cells such as human epithelial 
cells have much more complex machinery that is encoded in large genomic material and is 
bigger in size (few microns) than that of prokaryotic cells. Furthermore, a network of cells 
and extracellular matrix forms tissues which may extend to much larger sizes (few 
millimetres), as shown in Figure 1.3. This dissertation demonstrates the use of 
microfluidic-based systems to manipulate different biological entities for various 
biotechnology applications.   
Chapter 2 aims towards the development of a unit operation to prepare samples for 
long DNA applications, especially for genome mapping. In nature, the genomic material 
in cells are efficiently packed and well-guarded inside the nucleus, even during the cellular 
division process. However, extraction of a purified and intact DNA sample is vital for the 
correct in vitro decoding of the genomic data. Genome mapping, in particular, aims 
towards providing accurate location of the specific base sequence along the DNA 
backbone, which necessitates the use of long intact DNA for the analysis. Even though the 
genome mapping is a microfluidic-based system, it still relies on the conventional agarose 
plug for DNA extraction and purification. Furthermore, the workflow of genome mapping 
system requires a liquid DNA sample and the mechanical shearing of long DNA during 
pipetting introduces undesired short DNA fragments in the sample. Chapter 2 
demonstrates a microfluidic platform that can filter short DNA fragments from the DNA 
mixture and supply a purified long DNA sample for downstream applications.29 Moreover, 
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the device fabrication protocols were similar to those used for the fabrication of genome 
mapping chips and can easily be integrated into the existing workflow.  
In Chapter 3, we optimized the delivery protocol for the delivery of genetic material 
to adherent mammalian cells using non-viral delivery vehicles. Genetic medicine is a 
paradigm for personalized medicine but its delivery to the cell is inherently limited by 
cellular defense mechanism such as a structural barrier from the cellular and nuclear 
membrane as well enzymatic degradation inside the cells. The new chemical and biological 
vehicles are being clinically evaluated as potential carriers for the delivery of genetic 
material to the appropriate location inside the cell, mostly inside the nucleus for the plasmid 
delivery. For in vitro or ex vivo delivery, homogeneous and controlled delivery of payloads 
to the entire cell population is a crucial parameter for the therapeutic success. Moreover, 
as this therapeutic approach is advancing towards its clinical use, fast screening of various 
carriers is also necessary during the developmental phase. A major focus has been on 
designing delivery vehicles to overcome some of the natural barriers for efficient delivery. 
However, instead of designing new carriers, we employed commercial delivery vehicles to 
demonstrate engineering solution to expedite the delivery of gene carriers to cells surface 
and designed ways to controls this delivery at almost a single-cell level.30 
Chapter 4 discusses the ongoing efforts to develop an in vitro model for the study 
of host-microbe interaction in a human gut. The human gut is the house of a diverse 
microbiome that contributes to a unique microenvironment and is difficult to replicate in 
an in vitro setting. The animal model as well as human gut samples are acceptable platforms 
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to study interactions of the microbiome in the gut but are limited by experimental and 
ethical considerations. Conventional in vitro models involving a plate system does not 
allow several experimental conditions such as prolong cell viability during coculture of 
bacteria and epithelial cells, the dependence of the pathogenic response on the commensal 
microbiome, and selective microenvironment for bacterial and epithelial cells, especially 
for pure anaerobes. These limitations are attributed to the lack of human physiological 
condition including the absence of fluid flow and low oxygen concentration. These in vivo 
conditions are responsible for modulating the culture media conditions on the apical and 
lumen side of the gut. In Chapter 4, we demonstrate a combinatorial solution involving the 
engineering and biological approach to control the oxygen supply for host-microbe 
coculture. Furthermore, the use of this new system highlights the dependence of the 
virulence of Enterohemorrhagic E. coli (EHEC) in human epithelial cells on the oxygen 
flux into the system. 
Finally, Chapter 5 summarizes the salient features of the three platforms discussed 
in this dissertation. In addition, an outlook is provided on their advancements in the 
intended fields as well as new opportunities for the potential application of these devices.  
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Chapter 2 – Entropic trap purification of long 
DNA 
2.1 Introduction 
The last decade has witnessed massive improvements in the ability to read genetic 
information, ranging from short DNA fragments to whole human genomes. DNA can be 
read over short distances with single base pair resolution through DNA sequencing,31,32 as 
well as over long distances at lower resolution via genome mapping.33–36 The deployment 
of these new genomics methods has introduced new challenges in sample preparation. One 
major factor is the quality of the DNA samples, especially when working with long DNA 
molecules for genome mapping or long-read sequencing using the PacBio system.37 Long 
DNA samples are typically contaminated with short DNA fragments that arise from 
shearing of long DNA during processing. These short DNA fragments produce undesirable 
short reads in sequencing and noise in genome mapping. Effective use of these new 
genomic technologies, especially for de novo human genome applications,38 requires 
removing short DNA molecules prior to analysis. We have developed a continuous system 
that can filter short DNA fragments from a long DNA solution and can be readily integrated 
into chip-based genomic techniques. 
DNA separation is conventionally performed by gel electrophoresis, where the 
DNA moves through a network of pores under the influence of an applied electric field.  
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Under certain conditions, the mobility of the DNA is a function of its molecular weight.39 
Its simplicity and long history make gel electrophoresis ubiquitous in biology labs. But this 
technique has some drawbacks when used upstream of genomic applications that involve 
long DNA. First, gel electrophoresis requires long times to separate long DNA, typically 
many hours, owing to the low electric fields required to prevent the orientation of DNA 
molecules in the direction of the electric field40–42 and the long reorientation times during 
pulsed-field gel electrophoresis.39,43 Furthermore, gel electrophoresis is a batch process 
using large amounts of DNA. While these masses of DNA are desirable in some contexts, 
single-molecule genomic methods operate with much smaller numbers of molecules. There 
are also challenges when integrating gel electrophoresis into the genomics workflow. 
Generally, the DNA recovered from gel electrophoresis are in millimeter-sized agarose gel 
plugs that must be converted into microliter volume liquid solutions by enzymatic digestion 
of the agarose gel and pipetting. This creates problems for interfacing the sample 
preparation technique with the genomic tool without human intervention. Moreover, 
pipetting the liquid solution adds variability in sample quality due to random shearing of 
DNA in flow.44 Since most next-generation sequencing and mapping devices are already 
based on some type of microfluidic or nanofluidic system,45–47 designing unit operations 
that prepare samples upstream from the genomic systems and minimize manual handling 
of samples will help in addressing the shortcomings of gel electrophoresis while, in 
principle, permitting facile integration with the genomics technologies.   
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Microfluidics provides a wealth of potential solutions to the aforementioned 
problems with gel electrophoresis for next-generation genomics sample preparation.48 
Separation of biomolecules based on the size and mobility has been accomplished by 
various microfluidic electrophoretic methods49,50 where microfabrication has been used to 
fabricate controlled molecular sieve-like structures, such as slit-well motifs,51 post arrays,52 
nanowires,53 self-assembled colloidal arrays54 and miniaturized polymeric sieving 
matrices.55 Continuous filtration has been achieved using entropic trapping,52 
dielectrophoresis56 and fluid flow via deterministic lateral displacement.57  
For the purpose of filtering very short fragments from a long DNA sample, we 
propose that using a single stage of entropic trapping is a promising approach since it can 
provide simultaneous separation and concentration. Entropic trapping works on the 
principle that the long DNA must undergo conformational changes to enter a confined 
space and this creates an entropic barrier for their entry. This concept was first introduced 
to understand polymer dynamics in random porous media58 and was later applied to gel 
electrophoresis to explain the low-field mobility of DNA molecules close to the size of gel 
pores.59,60 In a microfluidic format, the entropic traps are formed by series of well and slit 
regions.51,61–65 Many configurations of electric field profiles and slit-well motifs have been 
used to achieve separation of DNA,61,65 RNA66 and proteins.62,63 A mechanistic 
understanding of these systems has been further explored experimentally64,67,68 and 
computationally.69–71 However, most systems have been designed to use hundreds of 
entropic traps in series to size a mixture of DNA molecules as an analytical tool, rather 
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than as a unit operation for sample preparation. In principle, such a system can be used as 
a filter by recovering the first part of the effluent containing the long DNA in one reservoir 
and diverting the remainder to a waste, since different size DNA will reach the end of the 
device at different times. However, this is a slow process because it requires time to 
concentrate the DNA at the injection point to create a sharp injection band, and the ensuing 
separation by molecular weight takes at least 30 minutes.51  
Here we present an entropic trap approach that can filter short DNA fragments from 
a long DNA sample, and simultaneously concentrate the latter, to improve sample quality 
for genomic applications. Our device is different than previous work using entropic 
trapping because we do not separate the DNA by molecular weight, but rather create a 
bandpass filter with a single stage of entropic trapping.51,64,72 Furthermore, our system 
provides a concentrated DNA plugs irrespective of the DNA concentration in the inlet feed 
as part of a continuous filtration process.63  Our system is based on the principle that the 
mobility of short DNA across the slit-well interface can be increased dramatically when 
compared to long DNA molecules if the system is operated at an electric field that it is 
lower than the field strength required to overcome the entropic barrier for long DNA but 
high enough to readily allow short DNA to surmount their smaller entropic barrier. To 
build a continuous filtration system, we designed our system such that it decouples the 
injection and the filtration processes by the simultaneous use of pressure and electric 
potential, providing flexible operation and efficient injection of DNA into the device. 
Furthermore, we employed similar fabrication procedures as those used to fabricate 
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nanochannels to study confined DNA.73–76 Our device could also be fabricated in silicon, 
making it, in principle, compatible with commercial genome mapping chips.47  The 
similarity in fabrication methods will help ease the integration of this filtration system with 
existing genome mapping techniques. We have explored how the filtration process can be 
tuned by changing the filtration voltage and filtration time, demonstrating the ability to 
optimize the system for particular applications. 
2.2 Working principle of filtration 
We begin here by first outlining the basic operating principles underlying our 
device. The discussion below is generic, and provides guidelines for operating the device 
for an arbitrary mixture. 
Device design  
The device, illustrated schematically in Figure 2.1, consists of two microchannels 
connected by parallel nanoslits. The interface formed between the channel and the slit 
provides the entropic barrier for filtration. In contrast to entropic trapping devices used for 
size-based separation,51,65,68 which typically comprise hundreds of entropic traps in series, 
the device in Figure 2.1 has 12 nanoslits in parallel. The two filtration zones highlighted in 
Figure 2.1 (main filtration and pre-concentration zone) are geometrically the same but have 
different roles during the filtration process, as discussed later. The device is designed to 
have nanoslits that are circa 90 nm deep and microchannel depths of 1 μm. The 
microchannels are connected at their extremities to ports for various purposes: the DNA 
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inlet port is used for injecting DNA into the device; long filtered DNA is sent to the DNA 
recovery port and short DNA fragments are shuttled to the filtration ports; and purge ports 
1 and 2 are used to control DNA motion in the microchannel for continuous operation of 
the device. The world-to-chip connectors for these ports were configured to allow 
simultaneous application of hydrostatic pressure and electric potential during device 
operation.77     
 
Concentration of DNA at the microchannel-nanoslit interface 
The device is designed to simultaneously concentrate and filter DNA at the 
microchannel-nanoslit interfaces. To demonstrate in a simple way how these dual effects 
are achieved, we constructed a resistor-based model to compute the electric potential at 
Figure 2.1 Schematic of the device. The blue regions represent microchannels. The two 
sets of colored nanoslits (gold and grey) represent the main filtration and pre-concentration 
zones discussed in Figure 2.2 and 2.3. The microchannels connecting the nanoslits are 
serpentine channels, seen in more detail in Fig 2.4. 
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each slit-channel interface, using Ohmic resistance for the channels and Kirchhoff’s law at 
the junctions, with fixed electric potentials at each port. We assume that the resistance of a 
given part of the device of length L is 𝑅 = 𝜎𝐿/𝐴, where A is the cross-sectional area 
available for ionic conduction and the resistivity 𝜎 is a constant throughout the device. For 
the resistance calculations, the microchannels have a 1 µm depth and the nanoslits have a 
depth of 100 nm and a length of 1 cm. All other dimensions were similar to the mask used 
for device fabrication. In this calculation, the two purge ports and the DNA inlet ports in 
Figure 2.1 were kept at ground, while the filtration ports were given a fixed potential Vf. 
As the DNA is a negatively charged molecule, it moves opposite to the electric field 
direction, i.e. towards the higher potential. The DNA recovery port was not included in the 
model because, in our experiments, the potential at the recovery port is floated to minimize 
backflow of recovered DNA. 
Figure 2.2 shows the predicted potential drop across the slits (ΔVi) and the electric 
potential near each slit-channel interface within the upper microchannel (Vi). Figure 2.2b 
shows that, based on this model, there are two symmetric local maxima in the electric 
potential on either side of the central purge port 1, which is the cumulative effect of the 
potential drops across the serpentine microchannel connecting the two parallel nanoslits. 
These maxima lead to DNA accumulation because they correspond to electric potential 
minima for the negatively charged DNA. These concentration points arise from the current 
of ions from the purge and inlet ports towards the filtration ports via the nanoslits. The 
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nanoslits are connected in parallel between the two microchannels, so the ionic current is 
distributed between nanoslits, leading to a non-uniform electric potential within the 
microchannels. Although there is a potential gradient within the microchannel, Figure 2.2a 
shows that the potential drop across each of the nanoslits is roughly constant. As a result, 
any of the nanoslits can serve as a filtration point for the DNA.  
Recognizing that this resistor model may be overly simplified, we also designed a 
3D COMSOL model of the device (Figure 2.3) and compared the electric potential profile 
from this more detailed model with that predicted by the resistor model (Figure 2.4). The 
COMSOL model predicts similar potential drops and two focusing zones in the device, 
indicating that the simple resistor model is a good approximation of the actual device 
Figure 2.2 Resistor model for the device design in Figure 2.1. a) Potential drop in each slit 
(ΔVi). b) Potential in the top microchannel of Figure 1 at each slit-channel interface (Vi). 
In both cases, the potentials are made dimensionless with the filtration voltage Vf. The six 
nanoslits on either side of purge port 1 are color-coded to indicate the main filtration and 
pre-concentration regions. The DNA recovery channel was not included in the resistor 
model. Note that the y-axis in (b) is plotted in reverse so that maxima in the electric 
potential are more easily interpreted as minima for the DNA electrostatic energy. 
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geometry. 
 
Separation by sequential injection and filtration steps 
To leverage the two filtration zones in our device, we designed an automated 
system to independently control the pressure and electric potential at each port. The DNA 
focusing regions on either side of the center purge port 1 serve as the pre-concentration and 
main filtration zones, with the objective to concentrate the DNA at the pre-concentration 
zone and then further purify the concentrated DNA mixture by subsequently transferring it 
to the main filtration zone.  The design in Figure 2.1 constitutes a single-stage separation; 
the system could be modified as a multi-stage separation simply by replicating this single 
stage and putting the DNA recovery port as part of the last stage.  
Figure 2.3 Dimensions of the microchannel and nanoslit used in the COMSOL model. 
Similar dimensions were used for the resistor model for comparison. There are 12 such 
parallel nanoslits connected by the microchannels as shown in the schematic (Figure 2.1). 
The device was modeled with a 90 nm deep nanoslit and microchannel depth of 1 µm. 
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The system was programmed to implement a sequential filtration process consisting 
of the injection and filtration steps shown in Figure 2.5. During the injection step, a constant 
air pressure (Pin) was applied at the DNA inlet, purge 1 and purge 2 ports, while all ports 
are electrically grounded. When the device is in operation, the pressure-driven flow 
accomplishes three aims: (i) recover the filtered DNA from the main filtration zone via the 
recovery channel; (ii) transfer the concentrated DNA from the pre-concentration to the 
main filtration zone; and (iii) inject fresh DNA from the DNA reservoir into the pre-
concentration zone. We found a pressure-driven flow to be superior to electrophoresis for 
these steps due to the relatively low electric field in the DNA inlet reservoir, which makes 
Figure 2.4 2D resistor model and 3D COMSOL model showed similar electric potentials 
in the microchannels and nanoslits. a) Plot of the potential drop in each slit for both 
models.  b) Plot of the potential at each slit-channel interface in the top channel. The red 
data correspond to the COMSOL model and the black data correspond to the resistor 
model. We observe similar trends in both plots. However, the absolute values are different 
due to the three-dimensional effects that are incorporated into the COMSOL model. The 
COMSOL model focused on the filtration region and did not have the long microchannel 
connecting the ports to the filtration region. To make the comparison between the two 
models, the resistor model was modified from the main text so that it is similar to 
COMSOL model dimensions. As a result, the absolute values shown here are different 
from those of Figure 2.2. 
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it challenging to have a high injection efficiency. Each injection step was followed by a 
filtration step, where a periodic pressure pulse was applied at the DNA inlet, purge 1 and 
purge 2 ports to help mix the DNA. At the same time, fixed electric potentials were 
maintained at all ports; the DNA inlet, purge 1 and purge 2 ports were kept at zero potential 
and the two filtration ports were kept at the filtration voltage (Vf) to provide the electric 
field in the slit that filters the short DNA. The DNA is focused in both zones of Figure 2.1 
at one slit-channel interface and the focused DNA are filtered over time at a rate that 
depends on their size (Figure 2.5c). The periodic pressure provided oscillations that 
assisted fast focusing of DNA in the main filtration zone while keeping them within the 
trap created by the potential gradient illustrated in Figure 2.2b.  
With the help of our continuous system, both the injection and filtration steps were 
repeated sequentially to achieve continuous filtration of the DNA sample. In this mode of 
operation, the DNA recovery channel is a crucial part of the design. The recovery port was 
kept at a floating potential, whereupon those DNA molecules that entered into the recovery 
channel during the pressure-driven injection step are not pulled back into the filtration zone 
during the electrophoresis-based filtration step. As a result, the device produces pulses of 
concentrated long DNA at the outlet. 
Tuning the separation performance 
The operation of the filter device is understood as the balance between two time 
scales.78 The first time scale is the residence time for the DNA at the interface between the 
27 
 
microchannel and the nanoslit. To a first approximation, the residence time is given by the 
duration of the filtration step t2 in Figure 2.5b. This estimate is an upper bound, as the DNA 
molecules require time to be transported to the interface when the voltage is applied. 
Moreover, the residence time differs between DNA molecules due to their different initial 
positions at the start of the filtration step. However, the residence time should be 
independent of molecular weight to a first approximation, since the free-solution 
electrophoretic mobility of DNA is independent of its size for molecules larger than 400 
base pairs.79,80 If anything, a size-dependent mobility, if were present, would enhance the 
filtration effect because it would slow the rate at which the longer DNA accumulate at the 
interface.  
The second time scale is the characteristic time for escape over the entropic barrier. 
The entrapment time 𝜏 of long DNA has been modeled with an equation,64,67,81 
𝜏 = 𝜏0exp(𝛼/𝐸𝑠𝑘𝑇) (1) 
where 𝜏0 and 𝛼 are parameters that depend on the size of the molecule, 𝐸𝑠 is the electric 
field strength in the slit and 𝑘𝑇 is the thermal energy. The prefactor 𝜏0 represents the 
frequency of attempts to escape an entropic trap. Prior work suggests that 𝜏0 is inversely 
proportional to the size of the DNA molecule because larger molecules present a larger 
cross-section at the interface, and thus have more opportunities to insert a hairpin into the 
slit.61,64 Equation 1 has been applied to model long DNA, and it is likely an overestimate 
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of the trapping time for short DNA.64 The other parameter 𝛼, is related to the free energy 
barrier for moving the polymer from the very weak confinement of the microchannel to the 
strong confinement of the nanoslit in the tilted potential energy landscape provided by the 
applied electric field. Simulation work suggests that 𝛼 depends on the molecular weight of 
the DNA at low and moderate electric fields; larger DNA experience a higher entropic 
penalty due to the reduction in conformational phase space upon entry into the slit.70 At 
Figure 2.5 Procedure to operate the device. Sequential injection and filtration modes 
correspond to changes in the pressure and voltage at each port. a) Values of the pressure 
and electric potential at each port during a cycle. b) Schematic of the pressure and potential 
profile applied at each port during the two modes of operation.  The pressure shown in the 
figure is the gauge pressure. c) Schematic of a potential use of the device to filter DNA 
mixture of short and long DNA molecules in the two filtration zones (main-filter and pre-
concentration) during the two modes of operation. The pre-concentration zone 
continuously receives DNA from the inlet reservoir. 
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higher electric fields, 𝛼 becomes independent of molecular weight for large DNA because 
its magnitude is governed by the entropic cost for inserting a “beachhead” of DNA into the 
nanoslit; the strong electric field then sucks the rest of the DNA into the slit.69 If the entire 
size of the DNA is smaller than this beachhead, then 𝛼 should remain a function of 
molecular weight for all electric field strengths. 
The remarkable feature of entropic trapping as a size-based separation is that the 
longer DNA elute first from the device because, under the relatively high electric fields 
used in those experiments, the dependence of  𝜏 on 𝜏0 is more important than the 
dependence on α.64 However, at sufficiently low electric fields, the parameter α will 
become the most important factor in governing the escape time because it appears in the 
exponential.  Indeed, previous studies suggest that there should be a sufficiently small 
electric field for which the entrapment time will be essentially infinite, i.e. DNA can be 
completely trapped at the slit-channel interface.64,67 In our experiments, we always 
observed finite entrapment time for long DNA at any filtration voltages that are sufficient 
to drive the DNA to the nanoslit-microchannel interface in a reasonable period of time.  
The filtration performance of our device can be tuned by considering the ratio of 
the two relevant time scales,  
𝛽 = 𝑡2/𝜏 (2) 
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for a given DNA size. If 𝛽 ≫ 1, then that size DNA should escape through the entropic 
trap and be filtered out. Most of the previous studies involving DNA separations using 
entropic traps trivially satisfy 𝛽 ≫ 1 because all of the DNA molecules cross the first 
slit.51,67,68  Conversely, if 𝛽 ≪ 1, then most of the DNA with that size should be retained 
in the microchannel and eventually shuttled to the DNA recovery port during the 
subsequent injection step. However, the intrinsic physics embodied by Eq. (1) implies that 
a single entropic trap will not provide an infinite selectivity since 𝛽 is always finite and 
non-zero. Moreover, it is worth noting that 𝛽 represents the characteristic time for the 
distribution of trapping times; even for 𝛽 ≪ 1, some of the molecules will still escape.   
2.3 Material and methods 
Device Fabrication 
The device fabrication follows the standard protocols for creating entropic trap 
devices outlined in Figure 2.6.65,73 Briefly, both the microchannels and nanoslits were 
patterned in S1813 photoresist (Shipley) using optical lithography followed by reactive ion 
etching using a mixture of Ar/CF4/CHF3 to transfer the patterns into a 4-in. diameter, 0.5 
mm thick fused silica substrate (University Wafer). The etch depth for the nanoslits and 
microchannels were controlled by optimizing the etching duration for each layer to achieve 
desired depths. The channel depths were quantified using a profilometer (KLA-Tencor P7). 
Final devices were further characterized with scanning electron microscopy (SEM, JEOL 
6610). After dicing the nine devices with a wafer saw (Disco DAD 2H/6T), access holes 
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for the ports were sand blasted (Danville). The completed substrate was then RCA-cleaned 
and thermally bonded to a 170 m coverslip in a 1000 C furnace (Thermo Fisher).73  
Nine devices were fabricated on each wafer. Ideally, each device has the same 
channel depth, but the variability in gas concentration inside the etching chambers caused 
some variation in the channel depth between devices. This variation in our system ranged 
from 88 nm to 103 nm for the nanoslits and 906 nm to 936 nm for the microchannels 
between different devices. The filtration experiments discussed below used a device with 
a nanoslit depth of 88 nm and microchannel depth of 906 nm. Figure 2.7 shows the 
profilometer profile for this device. The integrity of the final fabricated device was further 
verified using SEM.  
Figure 2.6 Steps involved in the fabrication of the device. 
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Sample Preparation 
Our experiments use two model systems: λ DNA (48.5 kilobase pairs, kbp, New 
England Biolabs; Rg  750 nm) as a prototypical long DNA molecule and 2 kbp DNA 
sample (New England Biolabs; Rg  100 nm) as a model short DNA contaminant.82 The 
DNA was stained with YOYO-1 fluorescent dye (Invitrogen) at a concentration of 1 dye 
molecule per 10 base pairs (bp) for λ DNA, and 1 dye molecule per 5 bp for 2 kbp DNA.83 
The stock DNA solution was prepared in 1X TBE buffer solution. For the experiments, the 
sample solution was prepared in 4X TBE buffer supplemented with 3% (w/v) 40 kDa 
polyvinyl pyrrolidine (Sigma-Aldrich) and 6% (v/v) β -mercaptoethanol (BME, Sigma-
Aldrich). The final solution for all experiments had a DNA concentration of 3 µg/ml.  
 
Experimental procedure and quantification 
The filtration device was mounted on a custom-built chuck that contains reservoirs 
for buffer solution as well as connections to simultaneously apply the hydrostatic pressure 
Figure 2.7 Profilometer data for the a) nanoslit and b) microchannels for the device used 
to produce the separation data in the main text. 
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and electric potential at each port. The filtration process for each DNA molecule was 
recorded with a sCMOS camera (ANDOR Zyla 4.2) using a 100x (1.4 N.A.) oil immersion 
objective on an inverted epifluorescence microscope (Leica DMI 4000B) with a 120 W 
metal halide source. Micro-Manager was programmed to synchronize the stage movement 
and camera recording during the filtration process.84,85  The air pressure and electric 
potential at each port were independently controlled using a LabVIEW program (National 
Instruments). For these experiments, all pressure related steps were performed at a gauge 
pressure of 2.5 kPa. The injection time (t1) was set as 35 s, which we found was sufficient 
for the filtered DNA to leave the main filtration region and the concentrated DNA to move 
from the pre-concentration region to the main filtration region. The short pressure pulse 
(t3) was applied for 2 s, with a delay (t4) of 28 s between the two pressure pulses. The 
operating pressure, injection and pulse time can be further optimized but were not 
evaluated in this work. The filtration process was quantified by measuring the decrease in 
the fluorescence intensity at the slit-channel interface during a filtration cycle. The final 
percentage decrease in the fluorescence intensity was averaged over two filtration cycles 
for each filtration condition. 
Device performance 
Figures 2.8a and 2.8b show scanning electron microscopy (SEM) images of a 
section of a completed device. The serpentine shape of the microchannels was designed to 
produce a potential drop within the microchannels in a compact geometry. Note that the 
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microchannel potential drop is required to produce the focusing predicted by Figure 2.2 
and the COMSOL model.  
Figures 2.8c and 2.8d show the basic operation of the device. In Figure 2.8c, we 
show the main filtration zone as it is filled with λ DNA molecules just after the injection 
cycle of Figure 2.5. Figure 2.8d then shows how these DNA molecules are concentrated at 
the completion of the filtration cycle of Figure 2.5. The pressure pulse for the DNA 
oscillation in the filtration cycle shifted the focusing of DNA in the direction of the pressure 
Figure 2.8 Validation of device fabrication and operation. a) SEM image of the upper 
microchannel near the center purge port 1 channel (Scale bar 20 µm). b)  SEM image of 
the final slit-channel interface that provides the entropic barrier for filtration (Scale bar 10 
µm). c) Fluorescent image of λ DNA molecules in the main filtration region near the third 
slit just after the completion of the injection cycle. d) Fluorescent image of the λ DNA just 
before the completion of the filtration cycle with the molecules trapped at the slit-channel 
interface. The white lines in (c) and (d) are included to indicate the channel boundaries, 
which are not visible in fluorescence images. 
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pulse, i.e. the DNA mostly focused on the third slit rather than the fourth slit predicted by 
the purely electrophoretic model in Figure 2.2b. However, the pressure pulse does not 
cause the DNA to jump to a new microchannel-nanoslit interface during the filtration step. 
Rather, it simply mixes the DNA at the interface to aid in filtration.  
One possible concern in our device is the possibility of migration of the DNA away 
from the walls due to the shear flow produced by the pressure pulses.86 However, we did 
not observe any significant impact of lateral migration during the filtration process. We 
attribute this outcome to two aspects of our system. First, during the filtration cycle, both 
the filtration zone and the concentration zone operate predominately under the influence of 
the electric field, with a small pressure pulse used to mix the DNA within the potential well 
created by the non-uniform electric field within the microchannel. These pressure pulses 
(duration t3 = 2 s) may not be long enough to develop a steady-state depletion layer near 
the wall. Second, as the DNA are focused near the slit-channel interface and form a DNA 
plug (as shown in Figure 2.8), the higher solution viscosity near the wall (created by the 
concentrated DNA plug) and screening of hydrodynamics near the wall at finite 
concentration, should further reduce the migration effect. While we suspect that lateral 
migration has a negligible effect on our separation, enhancing its role could aid the 
filtration process. Based on theory, the flow-induced depletion length will be larger for 
long DNA as compared to the short DNA.86 This implies that the long DNA should move 
away from the wall more than the short DNA, and thus reduce their escape attempt 
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frequency at the nanoslit entrance. The net effect is to increase the 𝛽 for short DNA when 
compared to long DNA and assist the filtration. 
We designed the device here for proof-of-concept experiments using pure 2 kbp 
and 48.5 kbp DNA separately. This separation is considerably more challenging than our 
targeted application in genome mapping, where the large DNA molecules are in excess of 
150 kbp, and thus provides a very stringent test of the principles underlying the filtration 
device.  These experiments, albeit more labor-intense than studying a mixture, allow us to 
quantify the filtration of short and long DNA molecules, respectively, without concern 
about spectral overlap and possible exchange of fluorescent dyes between molecules in a 
two-color experiment.  
The device was designed with a slit height close to the radius of gyration of the 
short DNA, but much smaller than that of the long DNA. The configurational degrees of 
freedom for the short DNA are not significantly reduced by entry into the shallow region, 
implying that they do not have much of a partition between the shallow and the deep region 
and that 𝛼 is relatively small. On the other hand, the long DNA molecules encounter a 
configurational entropy barrier associated with the deformation of the molecule in order 
for it to enter into the shallow region, whereupon 𝛼 is relatively large.71  We thus expect to 
observe different values of 𝛽 for these two species. The slit height is a key aspect in the 
device design, and it can be tuned to set the filtration cut-off at different molecular weights.  
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Like most filtration processes, our system entails a trade-off between selectivity 
and recovery of the filtrate. From Eqs. (1)-(2), our discussion of device tunability suggests 
two different approaches to alter 𝛽: (i) changing the filtration voltage, which affects 𝜏 
through changes in the electric field in the slit, Es; and (ii) changing the filtration time, t2. 
We consider each of these approaches separately in what follows. 
Effect of changing filtration voltage 
In our initial set of experiments, we examined the performance of the device at 
filtration voltages of 10 V, 12 V, and 14 V while fixing the filtration time at 600 s. Figure 
2.9 shows how the fluorescence intensity at the nanoslit-microchannel interface (Figure 
2.8d) changes as a function of time for these conditions using either 2 kbp DNA (Figure 
2.9a) or λ DNA (Figure 2.9b). These plots present the average of the fluorescence intensity 
over injection/filtration cycles in a single experiment, and these data correspond to the 
fluorescence intensity in the main filtration zone of Figure 2.1. We chose to study the main 
Figure 2.9 Percentage recovery of DNA for the filtration time of 600 s at different filtration 
voltages for a) 2 kbp and b) λ DNA molecules. Each filtration profile is an average of two 
filtration cycles. The color coding is the same for both panels. 
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filtration zone, rather than the pre-concentration zone, because the initial condition for the 
main filtration zone is the total amount of DNA to be filtered; for the pre-concentration 
zone, the filtration step involves a combination of filtration and continued injection and 
concentration of DNA from the loading reservoir, making it challenging to deconvolve the 
role of these two effects on the total fluorescence intensity.   
It is clear from the data in Figure 2.9 that the fluorescence intensity of the shorter 
DNA is decreasing as it is filtered through the device. In contrast, the longer DNA are 
retained at the slit. However, as noted in the context of Eq. (1), there is a finite escape time 
for the long DNA. Thus, as we run the filtration for a longer period of time, the longer 
DNA eventually begin to escape over the barrier.   
To convert the data in Figure 2.9 into a quantitative metric for the device 
performance, we defined the filtration efficiency to be proportional to the percentage of 
DNA (% fluorescence intensity) left in the main filtration zone at the end of the filtration 
cycle. For example, in case of 12 V, we recovered more than 40% of long DNA as 
compared to 20% recovery of short DNA when operated at the same condition.  
We repeated the experiment in Figure 2.9 multiple times, and the results are 
summarized in Table 2.1. The fluorescence intensity profiles for the data in that table 
appear in Figure 2.10. When the separation was performed on different days for the same 
operating conditions, the percentage recovery of long DNA between trials varied by up to 
15%. The corresponding day-to-day variation for small DNA molecules was 5% or less. 
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The variability in filtration, however, decreased with increasing filtration voltage. As such, 
the variability in the filtration of the large DNA may be attributed to the fluctuation in the 
mobility of DNA and the frequency of barrier hopping at relatively low electric fields. 
Previous studies have also reported mobility variations as large as 15%.67,87 These works 
tend to suggest that the variation in the mobility is more prominent at low electric fields 
and in the buffer solution with PVP.  Both of these conditions exist in our system. 
 Table 2.1 Percentage recovery of DNA molecules different trials and averaged DNA 
recovery for two DNA types as well as the selectivity of filtration at 600 s filtration time 
for different filtration voltages. Electric field in slit 3 was calculated for each filtration 
voltage using the resistor model shown in Figure 2.2. 
Filtration 
Voltage 
(V) 
Electric 
Field 
(V/cm) 
λ DNA (%) 2 kbp DNA (%) 
Trial 1 Trial 2 Trial 3 Trial 1 Trial 2 
10 8.75 60 75 46 30 40 
12 10.50 58 37 45 20 20 
14 12.24 41 29 36 8 12 
Filtration 
Voltage 
(V) 
Electric 
Field 
(V/cm) 
Average recovery (%) 
Selectivity 
λ DNA 2 kbp DNA 
10 8.75 60 35 1.7 
12 10.50 41 20 2.1 
14 12.24 35 10 3.5 
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The amount of short DNA removed from the solution increased from 60% to 90% 
on increasing the filtration voltage from 10 V to 14 V. This, in turn, increases the selectivity 
of filtration of short DNA as compared to long DNA in Table 2.1. But the improved 
selectivity comes at the expense of losing more λ DNA molecules with increasing filtration 
voltage. The recovery of λ DNA decreased from 60% to 40% with an increase in the 
filtration from 10 V to 14 V, consistent with our discussion of device tunability via Eqs. 
(1)-(2).  
Table 2.2 Percent recovery of individual DNA molecules for 600 s and 450 s filtration as 
well as the anticipated recovery at 450 s based on the filtration profile from 600 s filtration 
time. Electric field in slit 3 was calculated for each filtration voltage using the resistor 
model shown in Figure 2.2. 
 
Filtration 
Voltage (V) 
Electric 
Field 
(V/cm) 
Percentage recovery (%) 
600 s 
450 s 
(Prediction) 
450 s 
(Actual) 
2 kbp 
DNA 
12 10.50 20 35 36 
14 12.24 12 25 25 
λ DNA 
12 10.50 45 59 58 
14 12.24 37 48 54 
Effect of changing filtration time 
The second approach to control 𝛽 is to control the duration of the filtration cycle. 
Figure 2.11a shows the filtration profile of 2kbp and λ DNA, separately, for two different 
filtration times at a filtration voltage of 12 V. The fluorescence intensity profiles for the 
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two different filtration times nicely overlap on each other for both DNA sizes, indicating a 
high reproducibility within a given experiment. As a result, a filtration profile obtained for 
a large value of t2 should predict the filtration efficiency for shorter filtration time. Table 
2.2 summarizes the effectiveness of this approach, using the data obtained for a 600 s 
Figure 2.10 Different trials for the filtration of λ DNA (a-c) and 2 kbp DNA (d-f) at 600 s 
filtration time for various filtration voltages. The final percentage fluorescence intensity of 
these trials are tabulated in Table 2.1. 
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filtration time to predict the result for a 450 s experiment. The additional data for a filtration 
voltage of 14 V appear as Figure 2.12. Despite the variation in the mobility for different 
trials that we observed in Table 2.1, a similar recovery and overall filtration curves were 
obtained for the two different filtration times.  
Having demonstrated separately the two approaches for controlling 𝛽, i.e. filtration 
voltage and filtration time, we further computed the predicted selectivity profiles (Figure 
2.11b) for the filtration of λ and 2 kbp DNA at different filtration times for 12 V and 14 V, 
based on the data presented in Figure 2.10 and Table 2.1. The data in Figure 2.11b were 
obtained by taking the ratio of average fluorescence intensity for λ and 2 kbp DNA 
molecules at different filtration times. For each DNA size, the average fluorescence 
Figure 2.11 a) Percentage recovery of DNA for the filtration voltage of 12 V at different 
filtration times for i) λ DNA and ii) 2kbp DNA molecules. Each filtration profile is an 
average of two filtration cycles. The color coding is the same for both panels. b) Predicted 
selectivity profile for the filtration of λ DNA over the 2kbp DNA. The average fluorescence 
intensity profile for λ DNA and 2 kbp molecules used to obtain the selectivity at a particular 
filtration voltage is the average of three separate trials for λ DNA and two separate trials 
of 2 kbp DNA respectively, shown in Figure 2.10 
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intensity for particular filtration voltage is computed from the ensemble of all the 
independent trials.  
Figure 2.11b shows that for a particular filtration time, the selectivity increases with 
increasing filtration voltage and there is a higher selectivity for longer filtration times at a 
fixed filtration voltage. There is a small difference between the selectivity values at 600 s 
in Figure 2.11b and Table 2.1. This difference arises from the need to manually align the 
filtration profiles between different experiments for all filtration times to compute the 
average intensity profiles and selectivity. Overall, these results demonstrate the ability of 
our system to tune the filtration quality by balancing between the selectivity and recovery 
efficiency depending upon the need of the application.  
2.4 Conclusions 
We have designed and fabricated a filtration device that can preferentially remove 
the small DNA molecules from a DNA solution to improve the sample preparation for a 
genomic application. The filtration system operates as an automated injection-filtration 
process that concentrates and purifies the long DNA solution before a downstream 
application. The device operates continuously, producing plugs of concentrated long DNA 
at its outlet. The selectivity and recovery in the device are understood as the balance 
between the residence time at the nanoslit-microchannel interface and the escape time 
through the entropic trap.  For a given slit depth, the device performance can be tuned by 
either changing the duration of the filtration step or the filtration voltage. For proof-of-
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concept purposes, we used pure 2 kbp and λ DNA molecules to characterize the filtration 
process for our system. Moving forward, we envision this system as a short pass filter with 
a desired cut-off DNA size depending upon the application’s needs. The device can be 
optimized for a desired cut-off size by adjusting the design and operating parameters, 
including the slit count and the height of each slit.  
This work provides an important unit operation to improve the overall performance 
of genomic techniques, especially for genome mapping. Future work will focus on 
applying this system for genome mapping in nanochannels, where this filtration device is 
incorporated upstream of the nanochannel system to provide an integrated system.  
  
Figure 2.12 Data used to compute the percent recovery of DNA for the filtration voltage 
of 14 V at different filtration times for a) 2 kbp and b) λ DNA molecules. Each filtration 
profile is an average of two filtration cycles. 
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Chapter 3 – Fast, efficient and gentle transfection 
of human adherent cells in suspension 
3.1  Introduction 
The cellular delivery of genetic material is a valuable tool for many fields of 
biology such as genetics, biochemistry, molecular and developmental biology, and 
regenerative medicine. The last decade has seen rapid development in these fields. For 
example, the discovery of factors that allow generation of iPSCs from somatic cells88 and 
the ability to engineer the cellular genome with high specificity89 have transformative 
potential for personalized medicine. These and other biomedical research fields are reliant 
upon the successful delivery of nucleic acids into primary and immortalized cells, which 
requires (i) a delivery system that packages nucleic acids into nano/micro-particles,90 
followed by (ii) transport of the cargo to the cell surface and attachment to the plasma 
membrane, and finally (iii) internalization, intracellular trafficking and release of genetic 
material at a target intracellular location, typically the nucleus.91,92 Many viral and non-
viral gene delivery vehicles (GDVs)—with variable delivery efficiency and cell 
specificity—are available for the first step of this process to package genetic material of 
interest.90 For laboratory investigations, commonly used non-viral GDVs involve cationic 
lipids or polymers. These are particularly attractive as they can be rapidly prepared with 
various nucleic acid types (such as, mRNA, miRNA, lncRNA, shRNA, DNA) of different 
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sizes, combinations, and sequences.90,93 Furthermore, producing these materials is 
inexpensive and scalable.90 For adherent cells, the second step, endocytosis, typically 
involves plating a monolayer of cells, allowing cells to grow to near-confluency, and then 
exposing them to the GDV solution for several hours (commonly referred to as the 
transfection time). This step is limited by slow transport of GDV particles, variable rate of 
particle delivery to membrane in cell-cell contacts versus medium-exposed surfaces of the 
plated cells, and—critically— cytotoxicity.91,92,94 These limitations make cellular 
membrane transport an attractive target for improvement of the speed and efficiency of 
transfection in adherent cells.  
The similarities between GDV procedures and chemical reactor design for 
heterogeneous reactions suggest that the conventional transfection procedures can be 
significantly optimized. In particular, heterogeneous reactions are enhanced in slurry 
reactors, where the catalyst particles are in suspension.95 The challenge in applying this 
approach to gene delivery is that adherent cells stop dividing and undergo apoptosis when 
kept in suspension for an extended period of time.96 However, physical transfection 
methods, such as electroporation or nucleofection, succeed because the cells are kept in 
suspension for small durations.97 Therefore, we should be able to deliver GDV particles in 
suspension if the adhesion of the particle to the cell membrane occurs faster than the 
biological time scale for cell death. To this end, we propose a new suspension-based 
method to improve transfection efficiency of human induced pluripotent stem cells 
(iPSCs), primary cells, and immortalized cell lines. After the delivery process—achieved 
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in suspension—is complete, cells can then be plated for further culture expansion, or, if 
prepared in clinical grade, delivered to the patient.98 The innovation in our solution is 
recognizing different time scales in the delivery process; the GDV particles adhere to the 
cell surface in a much shorter time than it takes for them to cross the cellular membrane. 
This is based on the fact that cells take-up these particles through various endocytic 
pathways and have to undergo internal dynamic trafficking, which is both cell and GDV 
dependent.99 In contrast, attachment of GDV particles is usually due to non-specific 
interactions between membrane proteins and GDV particles. We employed bulk and 
microfluidic systems to understand how the exposure time of GDVs to the cell surface, 
spanning from seconds to hours, affects the overall delivery of nucleic acid to cells. 
3.2 Materials and Methods 
Cell culture 
Human cervical adenocarcinoma (HeLa) cells (American Type Culture Collection, 
Manassas, VA), primary human dermal fibroblasts from neonatal foreskin (HDFn; Life 
Technologies, Thermo Fisher Scientific Inc., Carlsbad, CA), and adult primary fibroblasts 
(PFB) were cultured in DMEM (Life Technologies, Thermo Fisher Scientific, Inc., 
Carlsbad, CA) supplemented with 10% FBS (Life Technologies, Thermo Fisher Scientific, 
Inc., Carlsbad, CA) and 1% AB/AM (Life Technologies, Thermo Fisher Scientific Inc., 
Carlsbad, CA) at 37˚C and 5% CO2. The HDFn were additionally supplemented with 1 
µL/mL EGF and 1 µL/mL FGF (PeproTech, Inc., Rocky Hill, NJ). The cells were cultured 
in 75-cm2 flasks and passaged at least once a week. All cells were confirmed to be 
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mycoplasma free using a MycoAlert™ Mycoplasma Detection Kit (Lonza Group Ltd., 
Walkersville, MD). 
Induced pluripotent stem cells (iPSCs) derived from naïve T cells were cultured on 
Matrigel® (Corning) in mTeSRTM1 (STEMCELL Technologies, Vancouver, BC, Canada) 
media. Cultures were maintained in 6-well plates. Media was changed daily, and cells were 
passaged at a ratio of 1/6 every 5 day, by gently scraping them from the well surface after 
incubating in PBS (Life Technologies, Thermo Fisher Scientific Inc., Carlsbad, CA) for 5 
minutes.  iPSCs were confirmed mycoplasma negative by PCR assay. 
GDV particle preparation 
GDV particles were formulated by complexing pDNA with transfection reagents 
FugeneHD (Promega Corporation, Madison, WI) and Glycofect (donation from Techulon 
Inc., Blacksburg, VA). Briefly, to make GDV particles with FugeneHD, 3 μl of FugeneHD 
per 1 μg pDNA was used and incubated for at least 15 min. For Glycofect, the GDV 
particles were complexed with pDNA at 20 N/P ratio (N/P ratio implies the number of 
secondary amines on the polymer backbones to the number of phosphate groups on the 
nucleic acid backbones to form the GDV particle solution)100 and incubated for 60 minutes. 
Cy5-labeled pCMV-lacZ (7.1kb; PlasmidFactory GmbH & Co. KG, Bielefeld, Germany), 
using Label IT® Nucleic Acid Labeling Kit (Mirus Bio, LLC., Madison, WI), was used to 
quantify attachment of the transfection reagents to the cell surface by measuring Cy5-
positive cells and for the gene expression assay, pZs-Green plasmid (3.3 kb; Clontech 
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Laboratories Inc., Mountain View, CA) was used to detect GFP-positive cells. For 
Glycofect systems, GDV particles were formulated in DNase/RNase-free water (Life 
Technologies, Thermo Fisher Scientific Inc., Carlsbad, CA) for bulk experiments, but for 
microfluidic device experiments, 5% dextrose sugar in water (Hospira Inc., Lake Forest, 
IL) was used instead of pure water to avoid cell lysis. For FugeneHD systems, GDV 
particles were prepared in OptiMEM (Life Technologies, Thermo Fisher Scientific Inc., 
Carlsbad, CA) solution for all experiments. The negative control samples in the 
experiments are denoted as “Cell only”, without any pDNA, or transfection vehicles and 
“pDNA only” with only free pDNA, without any transfection reagent, prepared in media 
similar to the GDV particle solution. All experiments were performed in triplicate, which 
are used to assess the error for each condition.  
Microfluidic device experiment 
Device prototyping: 
PDMS-glass hybrid microfluidic device was fabricated using the standard rapid 
prototyping and replica molding techniques, as described previously17,101,102. Briefly, the 
SU-8 structure was patterned on 4” silicon wafer (Nanofabrication Center, University of 
Minnesota, Minneapolis, MN) by using SU8-2050 negative photoresist (MicroChem, Inc., 
Santa Clara, CA). A pre-mixed 10:1 mixture of polydimethylsiloxane (PDMS) pre-
polymer and a curing agent solution (Sylgard184 kit; Dow Corning Corporation, Midland, 
MI) was poured over the patterned silicon wafer and cured at 70°C for at least 2 hours. The 
PDMS mold was peeled off from the wafer and holes were punched into the PDMS with 1 
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mm biopsy punch (Paramount Surgimed Ltd., New Delhi, India) to form the inlet and outlet 
of the device. PDMS replica was then bonded with the glass after plasma treatment using 
a plasma reactor (PDC-32G, Harrick Scientific, Pleasantville, NY). All channels in the 
device are 100 μm wide and ~70 μm deep. The fabrication workflow is outlined in Figure 
3.1. 
 
Prep-work: 
All the microfluidic supplies such as gastight glass syringes (SGE Analytical 
Science, Trajan Scientific Americas Inc., Austin, TX), Tygon tubing (Component Supply 
Co, Florida), and the device were thoroughly washed with three times as follows: (1) water, 
(2) 10% bleach, (3) water, (4) ethanol (190 proof), and (5) water. The complete setup was 
then filled with 7.5% BSA (bovine serum albumin) solution and incubated for 30 minutes. 
A new device was used for each experiment.  
Figure 3.1 Schematic of device fabrication: a) Fabrication of a negative mold of SU8 on a 
silicon wafer; b) Casting of a PDMS replica on the negative mold and bonding of the PDMS 
channel to glass slide using plasma treatment; c) Image of the microfluidic device. 
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Next, to make the cell suspension, the cells in flasks were first washed with PBS, 
then trypsinized using trypsin-EDTA (Life Technologies, Thermo Fisher Scientific Inc., 
Carlsbad, CA) and later neutralized by DMEM. This cell suspension was then centrifuged 
at 1000 rpm (201 X g) at +4˚C for 10 minutes (Eppendorf 5810R) to pellet the cells. The 
cell-pellet was then re-suspended in reduced serum media OptiMEM and counted using a 
hemocytometer. Finally, a cell solution at the required concentration of 750,000 cells/mL 
was created and loaded into the cell reservoir, which consisted of Tygon tubing (0.02 
inches inner diameter, 0.06 inches outer diameter, 420 cm) wound around an empty 50-ml 
centrifuge tube. A 1-mL syringe (inner diameter: 4.606 mm) filled with PBS, was used to 
pump the cell solution from the reservoir into the device, while another 1-mL syringe was 
filled with required GDV particle solution and pumped into the device at desired flow rate, 
using syringe pumps (Harvard Apparatus, Holliston, MA).  
Device setup: 
Individual syringe pumps were used to operate each syringe to administer cells and 
GDV particles separately into the device at a pre-determined flow rates. Both the syringes 
(cells and GDV particles) were mounted on to the syringe pump and locked in place. The 
tubing from the cell reservoir was then connected to the cell-inlet on the device. Similarly 
the tubing from GDV particle syringe was connected to the GDV particle-inlet on the 
device. Finally, one end of an outlet-tubing was attached to the outlet of the device, whereas 
the other end was placed in a vial containing PBS (collection vial). Flow and mixing 
profiles inside the microfluidic device were characterized by using fluorescein sodium salt 
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solution (460 nm; Sigma-Aldrich Co. LLC., St. Louis, MO) instead of the cell suspension 
and water (the GDV solution), for various flow rates.  Fluorescent images were analyzed 
using ImageJ software (National Institutes of Health). 
For real-time flow cytometry (FACSVerse; BD Biosciences, San Jose, CA), the 
collection vial was directly attached to the flow cytometer via an adapter. Schematic of the 
setup is outline in Figure 3.2. Similarly, for other assays that required these device-treated 
cells to be plated, the vial with cells was centrifuged at 1000 rpm (201 X g) at +4˚C for 10 
minutes (Eppendorf 5810R) to pellet cells. After removal of the supernatant, the cell pellet 
was re-suspended in the desired media (OptiMEM or DMEM) and subsequently added to 
wells in a cell culture plate. Various flow rates were studied using the microfluidic setup. 
Specifically, the flow rate of 10 µL/min for cell suspension and 40 µL/min for GDV 
particles was used for most GFP assays (at this flow rate, contact time between particles 
and cells is <1 minute). 
Cell surface attachment – Cy5 assay 
The cell surface attachment assay consisted of measuring percent positive cells for 
Cy5 using flow cytometry. The GDV particles were formulated using fluorescently labeled 
Cy5-pDNA. Data were acquired on flow cytometer for 2 to 5 minutes acquisition time. 
Cells positive for propidium iodide (PI; Life Technologies, Thermo Fisher Scientific Inc., 
Carlsbad, CA) were considered dead and gated out from analysis by using Flow Jo 
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software. 
 
Method-1: Bulk plated: 
A fixed number of cells were plated 24 hours prior to transfection: 50,000 cells/well 
in 12-well and 24-well plates for HDFn and HeLa cells respectively, and 120,000 cells/well 
in a 12-well plate for iPSC cells (<50% confluency at time of transfection). At the time of 
transfection, 264 µL of GDV particles solution (2.64 μg of pDNA) diluted with 528 µL of 
culture media, were added to wells to be transfected with GDV particles. Similarly, 264 
µL of pDNA (2.64 μg of pDNA) diluted with 528 µL of culture media was added to control 
“pDNA only” wells and 264 µL of water diluted with 528 µL of culture media was added 
to control “Cell only” wells. The cells were then allowed to transfect for a pre-determined 
time of 15 minutes or 60 minutes at 37˚C and 5% CO2. After the transfection time, cells 
Figure 3.2 Schematic of the experimental setup. Transfection media was filled in a syringe 
and the cell suspension was filled in Tygon® tubing, which is pumped by another syringe 
into the device. The outlet of the device is connected to a flow cytometer for real time-Cy5 
or collected in vial for GFP assay. 
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were trypsinized, washed with PBS and analyzed using flow cytometer for Cy5 positive 
cells. 
Method-2: Bulk suspension: 
Cells were added at a fixed concentration per tube, similar to that of the plated 
condition, to 5-ml-round-bottom Falcon-tubes. Next, 528 µL of culture media was added 
to each tube followed by 264 µL of GDV particles. Additionally, 264 µL of pDNA was 
added to “pDNA only” and 264 µL of water/culture media was added to “Cell only” 
samples, as a control. The cells were then allowed to transfect for a pre-determined time of 
15 or 60 minute at 37˚C and 5% CO2. Next, the cells were centrifuged, washed with PBS 
and analyzed on a flow cytometer for Cy5 positive cells. 
Method-3: Device Suspension: 
Cells treated on the device were collected in 500 µL PBS in a vial that was directly 
attached to the sample injection tube (SIT) on the flow cytometer. The acquisition rate on 
flow cytometer was higher than the outlet flow rate from the device, to enable real-time 
analysis of Cy5 positive cells. 
Gene expression – GFP assay 
The GFP gene expression assay was performed to quantify the transfected cells and 
measure the gene expression in the transfected cells. The GDV particles were formulated 
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using pZs-Green pDNA. Data was acquired on flow cytometer for 2 to 5 minute acquisition 
time. Propidium iodide stain was used to gate out dead cells from analysis. 
Method-1: Bulk plated: 
The cells were plated and transfected as described for the plated Cy5 assay. At the 
end of the transfection time, the cell monolayer was washed with PBS, followed by 
addition of cell culture media to the wells. The cells were then allowed to further incubate 
for specified durations (48 hours for iPSC and 72 hours for HDFn and HeLa cells). The 
media was periodically replaced (i.e., 24 hours) with fresh media specific cell type during 
incubation. Finally, the cells were washed, trypsinized and analyzed via flow cytometer for 
GFP positive cells and GFP intensity. 
Method-2: Bulk suspension: 
The cells were added to Falcon tubes and transfected as described for the 
suspension Cy5 assay. Similar to the plated assay, the cells were plated and incubated for 
a fixed duration (48 hours for iPSC and 72 hours for HDFn and HeLa cells). After 
incubation, cells were analyzed via flow cytometer for GFP positive cells and GFP 
intensity. 
Method-3: Device Suspension: 
Cells treated on the microfluidic device were collected in 1 mL PBS in 5 mL round-
bottom Falcon tubes with a total of 50,000 cells/tube. The cells were then centrifuged at 
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1000 rpm (201Xg) at +4˚C for 10 minutes. After centrifugation, the supernatant was 
removed to eliminate the excess unattached vehicles from the media/cell suspension. The 
cell pellet was then re-suspended in 528 µL of OptiMEM and transferred to wells (24-well 
plate for HeLa cells and 12-well plate for HDFn and PFB). Subsequently, cell culture 
media was added to each well and incubated for specified duration (48 hours for iPSCs and 
72 hours for HDFn and HeLa cells). Finally, cells were analyzed via flow cytometer for 
GFP positive cells and GFP intensity.  
Cell synchronization experiments 
To synchronize cells at the transition of G1/S phase in the cell cycle, a double 
thymidine block method was used. Briefly, cells were treated with 2 mM thymidine 
(Sigma-Aldrich Co. LLC., St. Louis, MO) in 10% FBS DMEM for fixed durations over 
two-day time prior to transfection. For the bulk-plated experiments, the cells were plated 
at a concentration of 30,000 cells/well in 12-well plate at 24 hours prior to the cell 
synchronization procedure. For the bulk suspension experiments, the cells were 
synchronized in a 75-cm2-flask with less than 50% confluency. The cells were first blocked 
at the transition of G1/S phase by treating the cells with 2mM thymidine containing media 
for 18 hours. Thymidine solution was then removed from cells to release them from the 
blocked phase in the cell cycle, by washing with PBS, and fresh media was added to 
wells/flask. Cells were further cultured for 9 hours in the fresh media, followed by a second 
block in cell cycle at G1/S phase for 15 hours by again adding a fresh thymidine containing 
media to cells. Prior to transfection, synchronized cells were released from the blocked 
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condition by washing cells with PBS to remove any thymidine from well/flask. These 
synchronized cells were then transfected with GDV solution containing 0.66 μg of pDNA, 
according to the procedure described earlier in the GFP assay section. For the bulk 
suspension experiments with HDFn, the GFP assay was performed 96-hour after 
transfection. The efficiency of cell synchronization was confirmed by fluorescent Vybrant 
Dye Cycle Ruby nuclear stain (Life Technologies,  Thermo Fisher Scientific Inc., Carlsbad, 
CA) using the manufacturer’s protocol. 
Statistical analysis 
Data in bar graphs are presented as mean ± standard deviations. Statistical analysis 
was performed using JMP software from SAS Institute (Raleigh, NC) and means were 
compared using either a Student’s t-test or Tukey’s test method, with p<0.05 being 
considered as statistically significant.  
3.3 Results and Discussion 
GDV binding during bulk transfection of adherent cells  
To test our hypothesis that the attachment of GDVs to cells is faster and more 
efficient in suspension than with a cell monolayer, we examined the delivery of GDV 
particles to the surface of human iPSCs. GDV particles were formed by the complexation 
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of Cy5-labeled pCMV-lacZ plasmid with FugeneHD, a commercial non-liposomal 
Figure 3.3 Flow cytometry analysis for the transfection of adherent cells (iPSC, HDFn and 
HeLa cells) with FugeneHD in bulk for Cy5 assay. Data are plotted as PI (y-axis) versus 
Cy5 (x-axis). Quadrant 1 (Q1) depicts cells that are only PI positive, Q2 denotes cells that 
are PI and Cy5 positive, and Q3 denotes transfected cells that are only Cy5 positive. All 
experiments were performed in triplicate and analyzed data are plotted in Figure 3.4. 
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transfection reagent. iPSCs were suspended in mTeSRTM1 media after gently scraping 
them from the well surface and exposed to the GDV solution for 15 minutes or 60 minutes, 
followed by a quick washing and centrifugation step to remove excess unbound delivery 
vehicles. Flow cytometry was then used to quantitate the percentage of live cells exhibiting 
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Figure 3.4 Comparison of delivery/gene expression (green region) of GDV particles to 
iPSc, HDFn, and HeLa cells in plated cells and in suspension. GDV particles were 
complexes of FugeneHD with pZs-Green plasmids (delivery). Data are reported as the 
percentage of live cells positive for GFP (n = 3). Representative raw flow cytometry data 
with gating are provided in Figures 3.3. [Note: “*” indicates samples are significantly 
different (P<0.05), “NS” indicates no significant differences between samples, all negative 
controls (cell only and pDNA only) < 0.5% and no significant differences between control 
samples for each cell types.] 
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a Cy5 signal (denotes GDV-cell attachment or internalization). Similar experiments were 
repeated with commercially available human dermal fibroblasts (HDFn) derived from 
neonatal foreskin, and human cervical adenocarcinoma (HeLa) cells that are a commonly 
used model for gene delivery studies. Figure 3.3 are the representative raw flow cytometry 
data with gating for different cell types and the analyzed data are plotted in Figure 3.4. As 
seen in Figure 3.4, the percent live cells associated with GDVs for all three cell types 
reached a maximum value within 15 minutes of exposure to the GDV transfection solution 
in suspension. In contrast, similar exposure of a cell monolayer (<50% confluent at the 
time of transfection) to transfection media had a significantly lower binding efficiency of 
GDVs to cells. The binding efficiency of GDVs to iPSCs is reduced as these cells tend to 
aggregate in cell clumps and shear stress during pipetting can cause differentiation of 
Figure 3.5 Successful binding (pink) of GDV particles (Glycofect complexed with Cy5 
labeled pCM-lacZ) to HDFn and HeLa cells in plated cells and in suspension. Data are 
reported as the percentage of live cells positive for Cy5 (n = 3). [Note: “*” indicates 
samples are significantly different (P<0.05), “NS” indicates no significant differences 
between samples, all negative controls (cell only and pDNA only) <0.5%, and no 
significant differences between control samples for each cell types.] 
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iPSCs. Nevertheless, transfection of iPSCs in suspension provided much better access for 
GDV particles to adhere to iPSCs, even in clumps, when compared to the transfection of 
these cells in a 2D culture. To test that this procedural improvement was not specific to 
only FugeneHD, we repeated the experiments using HeLa cells and HDFn with another 
delivery vehicle, Glycofect, a polymeric delivery vehicle developed in our lab.103 We 
observed similar results (Figure 3.5).  
Gene delivery for the bulk transfection of FugeneHD GDVs 
Fast and complete binding of GDV particles to the cell membrane is highly 
desirable but irrelevant if the bound particles do not eventually lead to internalization and 
the desired biological response, such as gene expression. To further examine transfection 
in terms of transgene expression after transfection of cells in suspension with the above 
conditions, we used pZs-Green plasmid (which contains a gene that encodes for green 
fluorescent protein, GFP) for the formulation of GDVs with FugeneHD. These experiments 
were similar to the binding assay with a minor modification. After washing the cells, they 
were plated and cultured for a fixed duration (48 hours for iPSCs and 72 hours for HDFn 
and HeLa cells). Thereafter they were analyzed for the number of live cells expressing GFP  
(Figures 3.6 and 3.7). Our results for iPSCs and HeLa cells demonstrate that attaching 
GDV particles in suspension results in at least a 2-fold increase in the overall efficiency of 
transfection (as evidenced by GFP expression) compared to conventional transfection in 
culture plates for 15 minutes of transfection time.  For both cell types, the majority 
population of live cells was successfully transfected (77% for iPSCs and 91% for HeLa 
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cells) by GDV particles within 15 minutes of exposure to GDV solution in suspension. 
Moreover, transfection of HDFn in suspension (4.1% GFP-positive live cells) was 
Figure 3.6 Flow cytometry analysis for the transfection of adherent cells (iPS, HDFn and 
HeLa cells) with FugeneHD in bulk for GFP assay. Data are plotted as PI (y-axis) versus 
FITC (x-axis). Quadrant 1 (Q1) depicts cells that are only PI positive, Q2 denotes cells that 
are PI and FITC positive, and Q3 denotes transfected cells that are only FITC positive. All 
experiments were performed in triplicate and analyzed data are plotted in Figure 3.7. 
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comparable to the plated condition (5% GFP-positive live cells) for a 15-minute 
transfection time.  
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Figure 3.7 Comparison of delivery/gene expression (green region) of GDV particles to 
iPSc, HDFn, and HeLa cells in plated cells and in suspension. GDV particles were 
complexes of FugeneHD with pZs-Green plasmids (delivery). Data are reported as the 
percentage of live cells positive for GFP (n = 3). Representative raw flow cytometry data 
with gating are provided in Figures 3.6. [Note: “*” indicates samples are significantly 
different (P<0.05), “NS” indicates no significant differences between samples, all negative 
controls (cell only and pDNA only) < 0.5% and no significant differences between control 
samples for each cell types.] 
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Cell synchronization to improve gene expression for Glycofect GDVs 
While we obtained high levels of GDV binding and transgene expression using the 
FugeneHD system, we found that Glycofect transfection reagent led to similar high binding 
efficiency of GDV particles in HDFn and HeLa cells (>95%) as compared to the negative 
controls (Figure 3.5). However, we did not observe any gene expression in either 
suspension or cell monolayer conditions. This negative result is contrary to the earlier 
reports of transfection in a cell monolayer for the 4-hour transfection time and may be 
explained by the use of a different reporter plasmid (luciferase versus GFP reporter 
system), or a lower dose of Glycofect particles in the experiments at 15 or 60 minute 
Figure 3.8 Flow cytometry analysis for the delivery (GFP assay) of GDV particles 
(Glycofect and pZs-Green) to HDFn cells synchronized at the transition of G1/S phase in 
15 minute transfection time for plated and suspension condition. Data are plotted as PI (y-
axis) versus FITC (x-axis). Quadrant 1 (Q1) depicts cells that are only PI positive, Q2 
denotes cells that are PI and FITC positive, and Q3 denotes transfected cells that are only 
FITC positive. All experiments were performed in triplicate and analyzed data are plotted 
in Figure 3.9. 
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exposure times as compared to the 4-hour transfection time.103–106 Earlier studies have 
reported that in the cell monolayer, Glycofect GDVs have slower kinetics of delivery104 
and that it is dependent on the cell cycle phase.105 Therefore, we synchronized HDFn at the 
transition of G1 and S phase107 and then transfected them with Glycofect GDVs for 15 
minutes. Transfected cells were incubated for an additional 24 hours as compared to our 
previous experiments (i.e., 96-hour incubation) prior to assaying for GFP expression. The 
transfection data were again quantified using flowcytometry (Figure 3.8) and the analyzed 
Figure 3.9 Successful suspension delivery of GDV particles (Glycofect and pZs-Green) to 
HDFn synchronized at the transition of G1/S phase. The cells were transfected for 15 
minutes, followed by 96 hours of incubation. As a control, a cell monolayer was transfected 
for 15 minutes followed by 72 hours of incubation. Data are reported as the percentage of 
live cells positive for GFP (n = 3) and pictorially represented as green circles in the 
figure. Representative raw flow cytometry data with gating are provided in Figure 3.8. 
[Note: “*” indicates samples are significantly different (P<0.05), all negative controls (cell 
only and pDNA only) <0.5%, and no significant differences between control samples for 
each cell types.] 
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data were plotted in Figure 3.9. Under these modified transfection conditions, a 6-fold 
increase was found for suspended HDFn synchronized at G1/S phase (25% GFP positive 
live cells), as compared to unsynchronized suspended cells (4% GFP positive live cells) 
for 15-minute transfection time, as shown in Figure 3.9. This result further supports our 
finding that transfection of cells in suspension does not impact the intracellular transport 
of transfection agents and that a 15-minute exposure time is sufficient for the transfection 
of cells in suspension.  
Microfluidic-based transfection of cells with GDVs 
 
To further investigate the suspension transfection method, we also explored the 
minimum contact time that can promote effective binding of GDV particles to cells. To 
provide increased control over the contact time, we fabricated a microfluidic device that 
Figure 3.10 Schematic of the microfluidic suspension transfection device. The figure was 
designed by Nilesh Ingle. 
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delivers two streams of GDV particles that sheath a central stream containing an almost 
single-file stream of cells (Figure 3.10). A serpentine channel geometry was added that 
facilitated mixing of fluids (Figure 3.11) and promote reagent/cell interactions in 
suspension.108 The device provides a contact time between the streams of less than one 
minute. Even with such a short contact time, we observed significant binding (>90%) of 
GDV particles to both HDFn and HeLa cells on the device (Figures 3.12). This result is 
robust to changes in the flow rates used on the device (Figure 3.13). Moreover, such high 
binding efficiency resulted in a significant percentage of GFP positive live cells (37% for 
HeLa cells and 4.6% for HDFn) compared to the negative controls (cell only), even for 
human adult primary fibroblasts (2.6%), as shown in Figure 3.14 and 3.15. The flow rates  
Figure 3.11 Mixing profile for total flow rates of 20 (blue), 50 (red), and 110 μL/min 
(green) in the microfluidic device. Water was used instead of the GDV solution and a 
solution of fluorescein was used instead of the cell solution. Ratio of flow rates for water 
and fluorescein solution was 4:1in all cases. Fluorescent images were taken at the inlet 
(solid line) and outlet (dash line) of the device (position marked in device image) and the 
fluorescent intensity was measured using ImageJ software.   
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(Figure 3.16a & c) had no significant effects on transfection, which is mainly attributed to 
Figure 3.12 Successful microfluidic binding (pink) of FugeneHD GDVs to HDFn and 
HeLa cells (pCMV-lacZ plasmid).  Flow rates were 10 μL/min (cells) and 40 μL/min 
(GDVs); the effective contact time between cells and GDVs was < 1 minute. Data are 
reported as the percentage of live cells positive for Cy5 (n = 3).  a) Representative raw flow 
cytometry data with gating and b) analyzed result of  the flow cytometry data. [Note: “*” 
indicates samples are significantly different (P<0.05) from “cell only” control, all negative 
controls (cell only and pDNA only) < 0.5%, and no significant differences between control 
samples for each cell types.] 
69 
 
Figure 3.13 Effect of the relative flow rate of the inlet streams on GDV attachment to the 
cell surface for HeLa cells transfected with Glycofect GDV particles formulated with Cy5-
labeled pCMV-lacZ plasmid. a) Representative raw flow cytometry data with gating for 
various flow rates. Data are plotted as PI (y-axis) versus Cy5 (x-axis). Quadrant 1 (Q1) 
depicts cells that are only PI positive, Q2 denotes cells that are PI and Cy5 positive, and 
Q3 denotes transfected cells that are only Cy5 positive. b) Analyzed data for the effect of 
flow rate on GDV attachment on cell surface. [Note: “*” indicates samples are significantly 
different (P<0.05) from “cell only” control, all negative controls (cell only and pDNA only) 
< 0.5% and no significant differences between control samples for each cell types.] 
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the similar mixing profile of the GDV and cell solutions inside the device at various flow 
rates (Figure 3.13). Similarly, the concentration of GDV particles in solution also had no 
significant effect on transfection (Figure 3.16b & d) because in a well-mixed environment, 
GDV particles quickly saturate the cell surfaces (<1 minute) and excess particles in solution 
will not have a significant effect on overall delivery at such a short time scale. Taken 
Figure 3.14 Flow cytometry analysis for the delivery (GFP assay) of FugeneHD GDVs to 
PFB, HDFn and HeLa cells using the microfluidic device. Data are plotted as PI (y-axis) 
versus FITC (x-axis). Quadrant 1 (Q1) depicts cells that are only PI positive, Q2 denotes 
cells that are PI and FITC positive, and Q3 denotes transfected cells that are only FITC 
positive. All experiments were performed in triplicate and analyzed data are plotted in 
Figure 3.15. 
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together, the data show that there are essentially no transport limitations to GDV particle 
binding in suspension at the microscale and bond GDV particles are sufficient to achieve 
significant gene delivery.  
 
3.4 Conclusion 
In summary, we have demonstrated that human stem cells, primary cells, and 
immortalized cells are effectively transfected in suspension. For laboratory applications, 
suspension transfection can reduce the protocol time by a full day, expediting the screening 
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Figure 3.15 Successful gene delivery (green) to primary fibroblasts (PFB), HDFn, and 
HeLa cells (pZs-Green plasmid). Flow rates were 10 μL/min (cells) and 40 μL/min 
(GDVs); the effective contact time between cells and GDVs was < 1 minute. Data are 
reported as the percentage of live cells positive for GFP (n = 3). Representative raw flow 
cytometry data with gating are provided in Figures 3.14. [Note: “*” indicates samples are 
significantly different (P<0.05) from “cell only” control, all negative controls (cell only 
and pDNA only) < 0.5%, and no significant differences between control samples for each 
cell types.] 
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of different gene delivery systems for a variety of biomedical uses. These improvements 
are potentially transformative for clinical applications, as our suspension transfection 
Figure 3.16 Optimization of delivery parameters for suspension transfection in a 
microfluidic device. Flow cytometry analysis for the transfection of HeLa with FugeneHD 
using a microfluidic device for a) different flow rates and b) different GDV concentration. 
Data are plotted as PI (y-axis) versus FITC (x-axis). All experiments were performed in 
triplicate. c) Effect of total flow rate on gene expression/delivery of GDV particles to HeLa 
cells in suspension with FugeneHD formulated with pZs-Green plasmid. Cell to GDV 
suspension flow rate ratio is 1:4. d) Effect of reagent concentration on gene expression for 
HeLa cells in suspension. GDV is FugeneHD complexed with pZs-Green plasmid with 1X 
concentration (2.64 μg pDNA/ 50,000 cells).  Flow rates were 10 μL/min (cells) and 40 
μL/min (GDVs). [Note: “*” indicates samples are significantly different (P<0.05) from 
“cell only” control, all negative controls (cell only and pDNA only) < 0.5% and no 
significant differences between control samples for each cell types.] 
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methods that also include a microfluidic system are fast, broadly applicable, scalable, 
amenable for high throughput transfections, and designed to ameliorate cell injury 
associated with gene transfer.  
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Chapter 4 – Micro-engineered cell culture systems 
to study the pathogen-host interaction  
4.1  Introduction 
The gastrointestinal tract is an extremely complex ecosystem with the largest 
microbial community in the human host, consisting of up to 1014 microorganisms over 500 
species.109,110 This diverse gut microbiome is often considered as a separate organ instead 
of just the collection of bacteria because of its significant role in human health and disease. 
Maintenance of the microbiome composition is crucial, and its disequilibria, commonly 
referred to as dysbiosis, leads to several gastrointestinal diseases. For example, the 
disruption in gut microbiota during antibiotic treatment or inflammation leads to increased 
susceptibility to intestinal infections.111,112 The altered microbiota structure has been 
correlated with increased risk of obesity, colon cancer, etc.113–115 Gut microbiota is also 
being considered as an intermediate target to alter the pharmacokinetics of an oral drug 
with the aim to improve the clinical response.116–118 Moreover, recent evidence suggests 
that the gut microbiota influences the host response to immunotherapy.119,120 All these 
potential benefits and disease management require an understanding of bacteria-host 
interaction, the mechanism of bacterial infection and host defense, the role of native 
microbiota in the pathogenic response and influence of local physiological conditions on 
bacterial infection. It is becoming increasingly clear that pathogens in the gut use signals 
derived from the host and commensal organisms to assess their environment and 
successfully deploy their virulence regime.121,122 However, the complexity and diversity of 
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the human gut have made it challenging to elucidate the mechanisms of the response due 
to the interactions between the host, microbiota and intestinal pathogens. Establishing an 
in vitro gut tissue model will enable systematic research on commensal-pathogen 
interactions in the GI tract.  
Enterohemorrhagic Escherichia coli (EHEC) is a deadly intestinal pathogen in 
humans that incorporates environmental, host and microbiota-derived signals in a complex 
signalling cascade to regulate its virulence genes. To colonize the intestine, EHEC employs 
a type III secretion system (T3SS) to inject effector proteins into host epithelial cells.123 
Bacterial effector proteins instigate host actin polymerization to form a “pedestal” structure 
around the bacteria. This leads to tighter adherence by the bacteria to host cells and eventual 
microvilli effacement and destruction of the intestinal epithelial layer. Physiological 
conditions, such as glucose and oxygen content, influence the bacterial adherence, 
expression of the T3SS and virulence of the pathogen.124–126 In particular, the low oxygen 
concentration has been postulated to be necessary for adequate adherence of EHEC for 
viral infection but the mechanistic understanding in human physiological condition is 
important for managing EHEC infection.125,126 There is a growing consensus on the 
significant influence of the gut microbiome on EHEC infection. It was recently observed 
in a cell culture infection model that the presence of the intestinal commensal organisms, 
Bacteroides thetaiotaomicron and Enterococcus faecalis, enhances expression of the 
EHEC T3SS and increase pedestal formation by EHEC.127 However, the mechanism 
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governing this interaction remains unknown and the co-culture of bacteria with the 
epithelial cells is necessary for its study.  
Applicability of in vivo or ex vivo tissue systems from humans and animals are 
limited by the fact that they are not always readily available owing to ethical 
considerations, short sample viability and tremendous variability among samples.110 For 
example, genetically modified mouse models have a different lifespan, diet variation and 
microbiome population as compared to humans. Furthermore, small animal models of 
infection often fail to reproduce comparable symptoms as those seen in human clinical 
diseases. In particular, EHEC does not produce disease in mice similar to that seen in 
humans. Most often the natural mouse pathogen Citrobacter rodentium must be used for 
in vivo studies and results are extrapolated to the human pathogen, EHEC.128 These 
limitations have advanced the development of many in vitro models that could provide the 
necessary physiological conditions required for the study and offer systematic control of 
experimental parameters.  
An engineered in vitro model using intestinal adenocarcinoma cell lines is one such 
lucrative option. These biomimetic systems can provide an organizational complexity 
mimicking the in vivo conditions for understanding various forms of regulation, which 
control bacterial infection when they colonize the gut. The most common “gold standard” 
for the in vitro model is the static well plate based assays, including multi-well, Petri dish 
and Transwell, which provides a fast, easy-to-use and standardized model for the studies.110 
However, the static well models often fail to predict clinical results, as they do not fully 
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consider the role of local microenvironment on the biological response because these 
models do not incorporate important in vivo physiological conditions such as fluidic flow 
and anaerobic conditions. The static culture conditions allow bacterial overgrowth and low 
cell viability that limit the understanding of the host-microbe interactions. 
Microfluidic systems are an increasingly popular tool to control the 
microenvironment for cell culture purposes.129 The attractive features of microfluidics 
include a laminar flow profile, small sample volume, temporal and spatial control on a 
chemical gradient, in-situ characterization, and availability of biocompatible materials for 
the device fabrication. Microfluidic systems have been successfully adopted for many cell-
based assays including chemotaxis, cell sorting and high-throughput screening. More 
recently, “organ-on-a-chip” microfluidic systems have been employed to support necessary 
requirements to recapitulate the minimal tissue- or organ- level functions and are being 
perceived as an alternative to animal studies for drug discovery and disease models.130,131 
Significant progress has already been made to mimic the functional response of human 
organs including the gut,132,133 placenta,134 eye,135 breast,136 heart,137 kidney,138,139 liver,140 
and lungs.141 Few gut-on-a-chip models are available in the literature with important gut 
physiology including highly differentiated human villus epithelium with high barrier 
property, continuous fluid flow and selective oxygen control that have been used for viral 
and bacterial infection as well as drug discovery.131 As these systems represent only the 
minimal function necessary for a particular study, having an adequate model is a 
prerequisite for the successful study. The ability to main the epithelial cell layer viability 
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and evaluate the infection response are the important necessities for the device design in 
this study.   
 Oxygen tension is an important parameter in an in vivo setting both for host cells 
as well as bacterial diversity, especially in the human gut.142 For example, a typical 
epithelial cell only experiences 3-9 % oxygen concentration inside a human body as 
compared to 20 % oxygen in atmospheric air.143 Similarly, the gut microbiome has a large 
population of strict anaerobes that flourish in the gut lumen without oxygen.144 For the in 
vitro systems, the oxygen concentration could be controlled in three ways – by a chemical, 
biological, or physical method. The chemical approach is a common way for culturing the 
bacterial systems by using anaerobic packs that remove the oxygen from the vessel 
vicinity.145 In the biological approach, facultative anaerobes can also create this 
environment by consuming oxygen through aerobic respiration, giving rise to an anaerobic 
environment which facilitates the growth of strictly anaerobic species.127 This is also the 
natural method to achieve the anaerobic condition in a human gut, where facultative 
anaerobes are the initial colonizers of the infant's gut and strict anaerobes bloom later when 
the environment is fully reduced.146 Finally, the physical method through passive diffusion 
involves the gaseous exchange of oxygen with inert carrier gas from the culture media.147 
This is the popular method in microfluidic systems, especially for the polymethyl siloxane 
(PDMS)-based devices, taking advantage of the high gas permeability (𝐷𝑂2 =
3 × 10−9 𝑚2/𝑠) in PDMS.148 The combination of high gas permeability and small 
diffusion length scale, the response time is fast in microsystems as in bulk.  
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In this work, we developed a microfluidic platform that facilitates the co-culture of 
bacteria and epithelial cells to study host-pathogen-commensal interactions during EHEC 
infection. This is of an urgent need for studies focusing on the role of commensal bacteria 
on the EHEC infection of epithelial cells.149 Many of the species in the native microbiota 
are strict anaerobes while foreign pathogens invade the gut tissue lining in anaerobic 
conditions. The conducive anaerobic conditions for the diverse microbiota are maintained 
through a population of enteric facultative anaerobes. The common method to study 
bacterial infection of epithelial cells in static multi-well assays fails to provide the 
necessary environment that can maintain epithelial cells for an extended period while still 
promoting bacterial adherence and virulence. Additionally, the lack of an anaerobic 
environment in a traditional well-based assay makes the interactions between EHEC and 
anaerobic species of the microbiota challenging. This specific limitation stems from the 
competing requirements for the epithelial cells and microbiome, and requires engineering 
tools to achieve selective environment mimicking the apical and lumen side of the gut. The 
blood in the apical side of the gut supplies oxygen for the viability of epithelial cells and 
the facultative anaerobes in gut lumen support anaerobic conditions. We have designed a 
system where oxygen is pumped into the lower blood-like channel to support epithelial 
cells viability while EHEC consumes oxygen in the apical gut chamber to provide the 
anaerobic lumen-like environment.  
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4.2 Materials and methods 
Device Fabrication 
The microfluidic device (Figure 4.1) provides a biologically relevant environment 
for establishing intestinal cell/microbial floral community in the partitioned 
aerobic/anaerobic-partitioned milieu. The upper and lower chambers are two 
microchannels for fluid flow and were fabricated using a two-step lithography process – 
fabrication of SU8 mold on silicon wafer and casting of PDMS replica on the SU8 mold.30 
Figure 4.1 a) Schematic of device with the intended use for cell culture. b) & c) are the 
side and top views of the assembled device respectively, highlighting device components 
and channel dimensions. 
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The upper channel in 1.5 mm wide while the height of the lower channel was 1 mm. Both 
channels were 150 µm high and a length of 5 mm. To enable on-device imaging of a cell 
layer and bacterial infection, a very thin PDMS layer was cast on the SU-8 mold by using 
spin coater at 150 rpm for 60 s. The device was assembled by sandwiching a porous PET 
membrane (pore size 0.4 µm; VWR) between the two channels by using thin PDMS mortar 
for the leak-proof bonding of three components and curing it on a 80 ⁰C hot plate 
overnight.150  The assembled device was bonded to the coverslip using plasma chamber, to 
provide mechanical rigidity as well as prevent evaporation through a lower channel inside 
the incubator. The schematic for the channel fabrication and the procedure to bond the PET 
membrane between the two channels are outlined in Figure 4.2.   
Cell culture 
Bulk cell culture 
Caco2 (ATCC HTB-37) and HeLa (ATCC CCL-2) cells were cultured in DMEM 
 
Figure 4.2 Workflow for the device fabrication involving photolithography and soft 
lithography process in silicon and PDMS respectively. 
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(4.5 g/L of glucose, Gibco) supplemented with 10 % FBS (Gibco).  Cells were grown on 
T-75 flasks (Thermo Fisher) and passaged at 80 % confluence (typically every 5 days). 
Culture media was replaced every three days.   
EHEC O157:H7 strain 86-24 transformed with pDP151, a constitutive-mCherry-
expressing plasmid, were cultured in LB media (Sigma) with 100 μg/mL Ampicillin. The 
standing culture was incubated at 37 ˚C overnight in aerobic conditions. For the bacterial 
infection, the overnight bacterial culture is diluted to the desired CFU concentration in the 
DMEM with 1 g/L glucose and was added to the apical side of the cell layer for its direct 
contact to the cell surface. 
Microfluidic cell culture 
The fabricated device was sterilized before using it for the cell culture by washing 
both channels with 70 % ethanol, followed by overnight UV-irradiation inside the biosafety 
cabinet. On the day of the experiment, the top channel was coated with the appropriate 
extracellular matrix (ECM) components and incubated in a 37 ⁰C incubator for at least 4 h 
to assist the adhesion of epithelial cells to the membrane surface. For HT29 and Caco2 
cells, rat-type collagen I (Corning) solution in PBS (1 mg/mL) was used,151 while the 
fibronectin (Sigma-Aldrich) solution in PBS (10 µg/mL) was used for HeLa cells. The top 
channel was then washed with PBS solution to remove the excess ECM solution. Cells 
were trypsinized from a T-75 flask and added to the top channel (6-8 × 106 cell/mL) with 
a pipette. Seeded cells were kept in an incubator for 1 h under the no-flow condition to 
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allow cell adhesion to the membrane surface.  After incubation, the top channel was washed 
to remove unattached clumps of cells, the bottom channel was filled with fresh media and 
the device was kept in an incubator for prolonged culture. Media was replaced each day 
and the cell layer was maintained for long durations (>10 days). A similar procedure was 
followed for the seeding of HeLa, Caco2 and HT29 cells. 
Bacterial infection on the coverslip 
The standard coverslip method was used as a positive control for the bacterial 
infection and establish the desired bacterial response that needs to be translated in the 
device before its use for the mechanistic study. The epithelial cells were seeded to a 
coverslip in a one well of a 12-well plate and the bacterial infection was performed after 
the two-day cell culture.127 On the day of the experiment, the bacterial inoculum was 
prepared in DMEM solution (1 g/L glucose, sodium pyruvate) of desired concentration, 
added to the well and incubated at 37 °C with a 5 % CO2 incubator for 3 h before changing 
the bacterial media with fresh media to maintain the viability of epithelial cells. The plate 
was further incubated for 3 h before fixing cells for imaging. 
Bacterial infection on a microfluidic device 
Figure 4.3 is the experimental setup for the co-culture of bacteria with epithelial 
cells. Briefly, the setup involved a continuous fluid flow in the bottom channel to provide 
continuous nutrition and oxygen to epithelial cells while facultative anaerobic bacteria like 
EHEC consumes the oxygen to maintain a microaerobic environment in the top channel 
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during its co-culture with epithelial cells. Various flow rates in the bottom channel were 
employed to understand the impact of oxygen supply on EHEC T3SS expression, which 
was quantified through EspA immunofluorescence (EspA is the major structural protein of 
the T3SS). The top channel was seeded with the desired bacterial concentration and co-
cultured with epithelial cells at 37 °C in an incubator at the stationary condition for 6 h. 
The standing bacterial culture in a top channel provided the necessary contact time to attain 
microaerobic condition for bacterial adhesion to cell surface and virulence.  
 
Confocal and wide field microscopy 
For immunofluorescence microscopic analysis, cells were grown in the 
coverslip/microfluidic device were fixed with 4 % (w/v) PFA, permeabilized with 0.2 % 
(v/v) Triton X-100. Hoechst Stain (Sigma) was used for nuclei counterstaining. Actin in 
permeabilized cells was stained with 1 µg/mL FITC-phalloidin to characterize cells layer 
on device and pedestal formation in response to infection. For the imaging of T3SS 
assembly, the EspA filament was stained with rabbit polyclonal EspA antisera at room 
Figure 4.3 a) The experimental setup for the bacterial infection. The fluid flow in the 
bottom channel was controlled by syringe pump and the bacterial cells are cultured in the 
top channel under quiescent condition. b) Schematic of epithelial and bacterial cells 
locations inside the device during the bacterial infection. 
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temperature followed by the staining with secondary antibody anti-rabbit IgG FITC 
(Sigma).152 The samples were hard mounted using ProLong Diamond Antifade Mountant 
(Thermofisher) and liquid mounted using SlowFade Diamond Antifade Mountant 
(Thermofisher). The prepared sample was visualized using Zeiss LSM800 laser scanning 
confocal microscopy as well as Zeiss axiovision widefield fluorescence microscope. The 
device membranes were imaged on-device at 20X and the membranes were peeled off the 
device for 63X oil objective. 
Oxygen measurement in bulk 
The dissolved oxygen was measured for standing bacterial cell culture with a fiber 
optic sensor (FOXY, Ocean Optics) dipped in the culture solution. The sensor was 
calibrated with deoxygenated media by purging nitrogen and fresh media equilibrated at 
atmospheric conditions.  
4.3 Result and discussion 
Epithelial cell layer on the device 
Epithelial tissues line the outer surfaces of organ and blood vessels as well as the 
inner surface of cavities in many internal organs such as the intestine. Many bacterial 
virulence factors cause damage to these epithelial tissues, thus breaking one of the defences 
against bacterial infection. Immortalized cell lines such as HeLa, HT29 and Caco2 cells 
are commonly used in epithelial cells and are thus used in this study. HeLa cells are a 
common epithelial cell type for the coverslip studies but do not truly represent the intestinal 
86 
 
lining, while the HT29 and Caco2 cells have been used in in vitro models to mimic 
functional characteristics of the human intestine.153  
The cell culture of adherent cells in microfluidic devices requires a strong adhesion 
of cells to the channel surface and resistance to the shear stress on its surface during the 
fluid flow. The use of extracellular matrix components such as fibronectin, collagen and 
poly-L-lysin have been used to assist adhesion of mammalian cells in a microfluidic 
channel and choice of these components are cell type dependent. For the HeLa and gut 
epithelial cells (HT 29 and Caco2 cells), fibronectin and rat type collagen I were used 
respectively. 
 
Figure 4.4 Confocal image of the epithelial cells in a microfluidic device. The cell nuclei 
were labelled with Hoechst stain (blue) and cell actin were stained with FITC-phalloidin 
(green). a) The confocal image of Caco2 cell along the microfluidic channel  (scale bar 500 
µm) and b) the representative confocal image on the channel for different cell epithelial 
cells: HeLa, HT29 and HT29+Caco2 cells (scale bar 200 µm). 
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The three epithelial cells were successfully seeded, and cell culture was maintained 
for at least 7 days. Figure 4.4 shows the confluent cells layer in the microchannel as 
highlighted by the staining of nuclei and actin using the Hoechst and phalloidin stains 
respectively. All three cell types form a living cell lining and its confluency was dependent 
on the cell type. For example, Caco2 and HeLa cells form a better confluent layer than 
HT29 cells. A mixture of Caco2 and HT29 was used to provide the necessary barrier 
property as well as the more functional characteristic of the human gut.  
  Bacterial virulence in epithelial cells on the coverslip 
To observe the level of EHEC virulence factor expression, HeLa and HT29 cells 
were infected with EHEC and the T3SS needle, which is composed of EspA protein, was 
stained via immunofluorescence as shown in Figure 4.5. The bacterial infection was 
performed at the seeding concentration of 107 CFU/mL. EHEC is a facultative anaerobe 
capable of growing in anaerobic conditions. EHEC has a high rate of oxygen 
consumption124 and the standing bacterial culture over the epithelial cell layer on the 
coverslip creates an anaerobic condition near the bacterial-epithelial cell interface as 
highlighted by the temporal graph of dissolved oxygen in the bacterial culture media. This 
setup supports the bacterial virulence response but significantly deteriorates the epithelial 
cell layer for prolonged culture. Therefore, the media must be replaced to prolong epithelial 
cell viability. This does not mimic the in vivo condition where the epithelial tissue line 
continuously receive oxygen from the apical blood side while the large population of 
facultative anaerobes maintains the anaerobic condition for a bacterial response.  
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A mathematical model for oxygen consumption for the coverslip setup 
EHEC uses several environmental cues such as the concentration of glucose, 
sodium pyruvate and oxygen to tightly control T3SS expression. Oxygen is an important 
variable as the in vivo conditions are drastically different from what can be simulated 
artificially. To better model a system that can closely recapitulate the in vivo condition in 
a microfluidic device, we need to understand the role of oxygen in modulating T3SS 
expression. 
The dissolved oxygen is significantly consumed in the media by the bacteria as 
compared to the epithelial cells adhered to the coverslip, while the oxygen is only supplied 
through the atmosphere. The doubling time for EHEC is between 15-30 minutes and for 
the experimental duration of 6 h, the EHEC reaches to the 109  CFU/ml within 3 h in the 
standing culture. The oxygen consumption also increases with the bacterial growth during 
a) b) 
Figure 4.5 Representative images of EHEC infection for 6h in a) HeLa and b) HT29 cells 
in the coverslip setup. Images show m-cherry expressing EHEC (red), Hoechst stained 
nuclei (blue) and the FITC immune-stained EspA (green). 
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the infection. The total oxygen consumption depends on the bacterial concentration 
(biomass) in the solution and the rate of oxygen uptake can be assumed to be independent 
of oxygen concentration (zeroth order kinetics) at a bacterial concentration. A quasi-steady 
state can be assumed at each bacterial concentration with the boundary conditions as a 
constant oxygen concentration at the top liquid surface and no oxygen flux at the coverslip 
surface. The oxygen concentration profile will be governed by the balance between the 
bulk consumption of oxygen and its diffusion from the top surface as related by the 
Damköhler numbers (Da).  Da for this system is represented as: 
𝐷𝑎 =
𝐾ℎ2
𝐷𝐶0
 (1) 
where 𝐾 = 𝐾0 × 𝑏 is the rate constant for the oxygen consumption that depends on 
the bacterial concentration (𝑏) in the solution and has a constant specific oxygen 
Figure 4.6 Steady state diffusion in a standing liquid. Concentration of oxygen molecule 
in liquid solution will be established by its diffusive influx through the surface as well as 
in bulk (Jy), while it is continuously consumed (𝑅v)in the bulk liquid. The schematic 
represents the mass balance and the boundary condition for small molecule in bulk. The 
mass balance at a steady state include the diffusion flux at element interface of area A and 
bulk consumption 𝑅v. 
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consumption rate (𝐾0), ℎ is the height of the liquid, 𝐷 is the oxygen diffusivity in water 
and  𝐶0 is the oxygen solubility in water at the experimental condition.  
Figure 4.6 highlights the mass balance for oxygen in an element for the bulk and 
the boundary condition that must be satisfied by the solution. The material balance for 
oxygen at steady state and a particular biomass is represented by: 
𝐼𝑛 − 𝑂𝑢𝑡 + 𝐺𝑒𝑛 = 0 (2) 
𝐴𝐽𝑦 − 𝐴𝐽𝑦+𝑑𝑦 + 𝑅v𝐴𝑑𝑦 = 0 (3) 
⟹
𝑑𝐽
𝑑𝑦
= −𝑅v (4) 
Fick’s first law relates the diffusion flux (𝐽) to the concentration gradient and is 
represented as :  
𝐽 = −𝐷
𝑑𝐶
𝑑𝑦
 (5) 
⟹
𝑑2𝐶
𝑑𝑦2
=
𝐾
𝐷
 (6) 
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The final concentration profile for at a bacterial concentration can be expressed by 
the following non-dimensionless equation for 𝐷𝑎 < 1: 
𝜃 = 1 −
𝐷𝑎
2
(1 − 𝜂2) (7) 
where 𝜃 = 𝐶𝑎 𝐶0⁄  and 𝜂 = 𝑦 ℎ⁄ . The solution to this equation must satisfy the boundary 
conditions of 𝜃 = 1 at 𝜂 = 1 and 
𝑑𝜃
𝑑𝜂
= 0 at 𝜂 = 0.  
 
For 𝐷𝑎 > 1, the oxygen concentration reaches to zero at a certain height in the 
liquid and the final equations representing all liquid height is given by:  
𝜃(𝜂) = {
1 −
𝐷𝑎
2
(1 − 𝜂2), ℎ ≤ 𝜂 ≤ 𝜂0
0, 𝜂0 < 𝜂 ≤ 0
, where 𝜂0 = √1 −
2
𝐷𝑎
 (8) 
Table 4.1 tabulates the rate of oxygen consumption and doubling time for EHEC in 
literature as well as calculated values for 𝐷𝑎.154,155 Based on the doubling time, EHEC will 
reach to 109 CFU/mL in ~2.5 h. The predicted high oxygen consumption with an increase 
in the biomass is consistent with the actual dissolved oxygen measurements in the standing 
bacterial culture using the DO probe as shown in Figure 4.7. These results suggest that the 
coverslip experiments were performed under oxygen tension near the vicinity of the 
epithelial cells surface. To maintain the epithelial cell layer viability, the oxygen-depleted 
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well media was replaced with fresh media after 3 h of infection. This is not the case in vivo 
as there is a continous oxygen supply to epithelia tissue lining from the blood side that 
supports tissue viability and provides a necessary barrier to the bacterial infection. A 
similar approach was adopted for the new microfluidic platform that used facultative 
bacteria as an oxygen scavenger and the blood-like bottom channel to control oxygen 
supply in the culture system.    
Table 4.1 Parametric calculation for oxygen consumption in coverslip setup.  
Max. oxygen consumption by E. coli (moles/CFU/h) 1.05 ×  10−17 
Diffusivity of oxygen in water (cm
2
/h) 0.117 
 Doubling time (min) 𝐺 ≡
𝑡
3.3 log10
𝑏
𝐵
 22.5 
Bacterial concentration 
(CFU/mL) 
𝑏 = 107 𝐵 = 109 
K  (mole/mL/h) 8.31 ×  10−8 8.31 ×  10−6 
Da 0.54 54 
𝜂0 NA 0.98 
Effect of flow rate on EHEC T3SS in epithelial cells 
EHEC infects both the human and bovine gut, where robust colonization is 
dependent on its T3SS expression.126,127,156 While building the in vitro model, it is 
necessary to simulate both conditions — the coverslip and the in vivo like conditions, to 
make full use of the already known results based on existing models and then provide a 
more realistic prediction for various disease manifestations in the human body. In this 
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effort, we performed the bacterial infection on microfluidic devices with standing bacterial 
culture in the top channel that consumes oxygen in the top channel and limited the oxygen 
flux from the bottom channel by controlling the fluid flow in the bottom channel. To 
visualize levels of T3SS expression, immune-staining of EspA was performed to 
characterise the extent of infection in response to the oxygen tension. 
The bacterial response was first evaluated at 50 µL/h flow rate in the bottom 
channel. Under such conditions, the T3SS was not observed in HT29 cells devices for 6 h 
incubation. Prolonged infection for 9 h showed few cells with T3SS expression, while very 
long infection duration of 24 h showed significant T3SS expression. Performing a long 
infection on the device also deteriorated the epithelial cell layer in the device. All epithelial 
cells were washed out of the channel during the staining process indicating high bacterial 
infection for the 24 h condition. The minimum flow rate of fresh media (based on Table 
4.1) necessary to match the oxygen demand at inoculation density (107 CFU/mL) is ~0.3 
Figure 4.7 a) Schematic of coverslip setup used for bacterial infection. This setup was used 
to measure the oxygen concentration in media over time, which is similar to the coverslip 
condition. b) Temporal measurement of dissolved oxygen (%) in media using a DO probe 
for 6 h duration. 
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µL/h and it increases to 30 µL/h for 109 CFU/mL. At high flow rate condition (50 µL/h), 
the oxygen supply to the device is higher than the oxygen consumption by the epithelial 
and bacterial cells. This suggests that the high oxygen concentration delays bacterial 
infection in epithelial cells, which is mainly attributed to the decrease in the bacterial 
adhesion to the epithelial cell surface.  
If the adherence of epithelial cells and T3SS expression are oxygen dependent, 
controlling its flux by the fluid flow in the bottom channel should reproduce a similar 
phenotype as observed in coverslip experiments. To further verify the impact of oxygen on 
T3SS expression in EHEC infection of epithelial cells, we compared the response of on-
device infection at two flow rates: 0.5 and 50 µL/h for 6 h infection. The low flow rate 
value was estimated based on the oxygen consumption rates used for the bulk model and a 
100-fold increase flow rate represent the oxygen-rich condition, as shown in Figure 4.9 and 
4.10. Under the limited oxygen supply, all types of epithelial cell devices expressed a 
significant increase in EspA expression within 6 h of infection at 0.5 µL/h as compared to 
the high flow rate condition of 50 µL/h.  
The microfluidic model works on the idea that the bottom (apical side) channel 
would be the only source of oxygen available for consumption by the epithelial and 
bacterial cells. While the oxygen is necessary for the epithelial cells, limited oxygen  
(microaerobic) condition enhances bacterial adhesion factor for EHEC which in turn assist 
higher bacterial infection. We hypothesise that EHEC self-regulates the oxygen condition 
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analogous to the in vivo condition where the large pool of facultative anaerobes assists in 
achieving the anaerobic/microaerobic environment in the human gut.   
4.4 Next generation microfluidic system  
Our current model successfully demonstrates the impact of oxygen on the bacterial 
response for the facultative anaerobe (EHEC), but the system does not support the culture 
of only strict anaerobes which need low oxygen concentration to grow. Certain 
modifications are necessary to independently manipulate the oxygen concentration in the 
top channel. This will be useful in two ways – as a control device that supplies oxygen to 
the top channel to compensate for the oxygen usage by the bacterial cells and secondly, to 
Figure 4.8 Representative image for the EspA expression due to EHEC infection in HT29 
cells at 50 µL/h for the 9 h and 24 h infection. Images show m-cherry expressing EHEC 
(red), Hoechst stained nuclei (blue) and the FITC immune-stained EspA (green). Scale bar 
20 µm. 
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remove oxygen from the top channel irrespective of the type of bacteria present in the 
channel. The first role will help validate the hypothesis that EHEC infection is oxygen 
dependent that was observed at low flow rate while the second usage of the new device 
will be to provide an anaerobic condition for strict anaerobes for more advanced parametric 
studies. Taking advantage of the high gas permeability in PDMS, an additional control 
channel will be added to the existing design for the operational flexibility.157  
We can modify our system to remove oxygen from the top channel through its 
diffusion into the carrier gas by adding a third channel over the top channel separated by a 
thin PDMS layer to provide liquid barrier and gas permeation, as shown in Figure 4.11. 
Figure 4.9 Representative image for the EspA expression due to EHEC infection for 6 h 
in HeLa cells at different flow rates: a) 50 µL/h and b) 0.5 µL/h. Images show m-cherry 
expressing EHEC (red), Hoechst stained nuclei (blue) and the FITC immune-stained EspA 
(green). Scale bar 20 µm. 
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The three-layered device can be fabricated using the soft lithography. The control gas 
channel would be cast on the SU-8 mold on the silicon wafer while the middle bacterial 
channel is spin coated on a SU-8 mold to control the thickness of the PDMS layer and 
control the rate of oxygen removal through carrier gas. The control channel fabricated 
using bulk casting and bonded to the spin-coated PDMS casting on the SU-8 top channel 
mold before peeling it off the mold. The assembled channel and the bottom channel will 
sandwich the trans-well membrane similar to that shown in Figure 4.2.  
For the new setup to work as a negative control for the study, the control channel 
needs to have a continuous flow of oxygen-saturated PBS that will supply the oxygen to 
the bacterial channel and counter the oxygen usage by the bacterial uptake. If oxygen is 
indeed such an important factor for EHEC infection, this indirect supply of oxygen should 
Figure 4.10 Representative image for the EspA expression due to EHEC infection for 6 h 
in a) Caco2 cells and b) HT29+Caco2 cells at 0.5 µL/h. Images show m-cherry expressing 
EHEC (red), Hoechst stained nuclei (blue) and the FITC immune-stained EspA (green). 
Scale bar is 20 µm. 
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show low/no EspA expression similar to the high flow rate condition in the earlier device. 
The use of PBS instead of air will prevent the drying of the bacterial channel due to the 
evaporation of water through the control channel.  
On the other hand, for the device to act as an anaerobic chamber for strict anaerobes, 
pressured nitrogen flow through the control channel to strip the oxygen from the bacterial 
media. The carrier gas in the control channel should be saturated with water to prevent 
water evaporation during the experiment. An important requirement for this system to work 
is the design of a pressure system to control the pressure and composition of the carrier gas 
in the channel. The anaerobic condition in the bacterial channel could be verified with the 
luminescence measurement of oxygen sensitive dye, Tris(4,7-diphenyl-1,10-
phenanthroline)ruthenium(II) dichloride complex (1 mg/ml) in PBS.158  
Figure 4.11 a) Schematic of modified device with the additional control channel. b) 
Schematic of epithelial and bacterial cells location inside the device along with the control 
channel during the bacterial infection. Flow of oxygen-rich media or nitrogen gas will be 
controlled in the top channel depending on the intended role of the new device as a control 
device or anaerobic micro-reactor respectively. 
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4.5 Conclusion 
This is a first attempt to use microfluidic tools to study the mechanism of EHEC 
virulence especially in the more in vivo like setting. The first design successfully elucidated 
the role of oxygen for EHEC infection in epithelial cells and demonstrated the ability to 
use facultative anaerobes in a microfluidic device to modulate oxygen. This is an ongoing 
effort to better the in vitro model for a more realistic study to predict in vivo response. 
Furthermore, we propose an advanced model that will allow the culture of strict anaerobes 
as well as facultative anaerobes for the parametric study. For example, to investigate the 
contribution of native gut microbes towards the EHEC infection, it would require co-
culturing commensal gut bacteria before introducing a pathogen into the system. Our 
interdisciplinary approach helped to develop a unique as a well as a simple solution for the 
mechanistic understanding of a human gut. Indeed, interest in microbiome studies extends 
far beyond EHEC, as it has been linked to obesity, colon cancer, infectious disease, brain 
development, Crohn's disease and many other illnesses. The current system can further be 
modified to handle engineering as well as biological problems related to the gut, such as 
prolonged co-culture as well as drug-resistance bacteria.  
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Chapter 5 – Conclusion and perspective  
The three applications described in this dissertation demonstrate the benefits of 
microfluidic technology in overcoming some of the challenges in the field of 
biotechnology. Chapters 2, 3 and 4 describe the proof-of-concept results for the technology 
and further advancements can be made in the device design or its application in other fields, 
for each of the three technologies. This chapter discusses some plausible future 
improvements in the device design and operations that will help in the advancement of 
their applications in various fields. 
5.1 Entropic trap purification of long DNA 
This is still an ongoing work in our group with many potential avenues to explore 
its use for long DNA applications such as genome mapping. This includes the optimization 
for device design and operation, filtration of different biological molecules, and the 
characterization of filtration performance for real-life applications.  
There are several aspects of optimization possible in our filtration system. In terms 
of device design, we have employed six slits each for the pre-filtration and main-filtration 
zone. These nanoslit counts were retained during the initial development process and can 
be optimized using the resistor model. Furthermore, the filtration system design in Chapter 
2 is a unit operation and multiples of such operations can be arranged in series to achieve 
desired purity, as shown in Figure 5.1. For single stage filtration, we have demonstrated 
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that the selectivity and yield complement each other and must be optimized further for each 
application. Multiple stages can help achieve higher purity without compromising the DNA 
yield. Moreover, the height of the nanoslit dictates the filtration performance and the multi-
stage filtration can have various nanoslit heights for sequential filtration of different sizes 
of DNA. Further optimization will involve tuning the operating parameters such as 
filtration voltage, filtration time, injection pressure, and injection time. For the 
advancement of the filtration system to commercial use, these design and operation 
parameters will have to be explored in detail for each application.  
 
A major bottleneck in the complete characterization of our device is the recovery 
of the filtered DNA from the device. This is less of an issue when it is used for our intended 
Figure 5.1 Schematic of the proposed dual-stage filtration. The two stages can have 
different slit height depending on the application. 
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applications in the field of genomics. Most of the genomic application are microfluidic-
based and the current system can be easily integrated into the upstream, thus eliminating 
the need to recover the filtered DNA. As discussed in Chapter 2, the device performance 
was characterized by quantifying the filtration of different-sized DNA molecules under 
similar operating conditions and we demonstrated high selectivity for long DNA molecules 
as compared to short DNA fragments. Moving forward, it is important to characterize the 
device performance for specific application and genome mapping is the ideal application 
of this device. Confining DNA in nanochannels at laboratory scale is already well-
established, including the device design, fabrication as well as experimental protocols.159 
The device design in Figure 5.2 is one way to combine our device with nanochannels and 
is already under trials in our group. This approach of incorporating the nanochannel at the 
downstream will not only help characterize the filtration performance; it can also be used 
for the genome mapping of clinical samples.  
In addition to the size of the molecule, it must be negatively charged in order to be 
focused at the slit-channel interface during the filtration step.  As the development work of 
this device is being focused towards genome mapping, this filtration system can have 
additional benefits for removing smaller biological entities such as RNA and proteins, 
which are also common impurities in a clinical sample along with short DNA fragments. 
This filtration system will also be advantageous to remove free dye molecules from the 
solution that are difficult to remove during chemical processes. Free dyes are often 
removed using drop-dialysis, but it causes further fragmentation during pipetting as well 
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as 
sample loss. Molecules such as ChromaTide™ Alexa Fluor™ 546-14-dUTP, commonly 
used for labelling long DNA, are also negatively charged and can be filtered out using our 
filtration method.77  
5.2 Fast, efficient and gentle transfection of human adherent cells in 
suspension 
Our work discussed in Chapter 3 highlights the different time scales involved in the 
delivery of non-viral gene delivery and demonstrates its use to expedite the delivery 
process. Recently, this idea was further explored by another research group, to deliver 
plasmid in mouse embryonic stem cells in suspension within 5 minutes of transfection 
Figure 5.2 The proposed device for incorporating nanochannel with the filtration system 
for genome mapping applications. This device is being fabricated and tested in our group 
by Hui-Min Chuang. 
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time.160 As the field progresses from the proof-of-concept experiments towards its clinical 
application, it will be necessary to adopt the protocol for more practical applications such 
as large-scale manufacturing.  
Non-viral delivery vehicles have the advantage of large payload, low cytotoxicity, 
low production cost, and easy manufacturing scalability, but they face several challenges 
such as low colloidal stability, short half-life, low delivery efficiency, and long delivery 
time. Our work described in Chapter 3 is a convenient way to expedite the delivery time 
through fast attachment of GDV to the cell surface. Furthermore, this can be useful to 
overcome the limitation of low efficiency by performing multiple transfections of the cell 
population.161 The unique control on the delivery of GDV at a single cell level achieved 
through microfluidic-based transfection in our work will be very useful for gene editing 
applications, especially for the CRISPR-Cas9 system, where high copy number may cause 
undesirable off-target editing.  Sequential delivery of different payloads for gene editing  
can also be easily achieved with our protocol. A major challenge in translating our current 
protocol for multiple transfections is the ability to maintain cell viability of adherent cells 
in suspension. For single transfection, we addressed this issue by performing the 
attachment step quickly (<1 minute in the microfluidic system) and replacing it into fresh 
culture media. However, in the context of multiple transfections, a major challenge will be 
to detach cells from the solid surface for suspension transfection multiple times. Such a 
fast change in cell physiology will be detrimental to cells and may increase cytotoxicity.  
Another difficulty with current commercial transfection reagents is the low colloidal 
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stability of delivery vehicles in serum-rich media. Therefore, many of these transfection 
protocols require less-favorable media condition for transfection and the transfected cells 
are replaced with serum-containing media for the intracellular trafficking of GDVs.  
The advancement of the new protocol to clinical application will require its 
integration with the usage of microcarrier that supports a sustainable culture of anchorage-
dependent mammalian cells in suspension. Microcarrier has been a popular choice in the 
pharmaceutical industry for the large-scale production of vaccine and biologics. Large 
development work on microcarrier is already available for the cell culture applications, 
including size, materials, porosity and surface properties. Many soluble microcarriers have 
also been commercialized for such applications.162  Adaptation of microcarriers for gene 
delivery purposes is in its early stages, as shown in Figure 5.3,163 and is expected to be 
more widely used for gene-based therapy. Continuous microcarrier-based culture is already 
being adopted in a microfluidic system.164 We envision the new design for integrating 
microcarrier with our protocol to involve three stages: (i) gradual replacement of serum-
rich media with appropriate transfection condition; (ii) mixing of carriers with delivery 
vehicles and; (iii) finally replacing transfection media with fresh culture media for normal 
culture. This can be done both with the bulk system, similar to that shown in Figure 5.3, or 
a continuous microfluidic reactor that can be designed to achieve short contact time. From 
the delivery point of view, solid microcarriers will be preferable with low cell confluency 
to achieve higher delivery performance.  
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5.3 Micro-engineered cell culture system as a human gut model 
Chapter 5 is an excellent example of how to adapt an existing design to build the 
tools necessary for a study. We demonstrated in chapter 5 that the dual-channel with 
controlled oxygen flux recapitulates some of the in vivo conditions and demonstrated its 
use for host-pathogen interaction for EHEC in a human epithelial cell system.  As outlined 
in the chapter, these technological developments are not limited to the EHEC pathogen but 
can have a more general impact on the study of the role of microbiota in human health. We 
have further outlined some of the immediate future directions in terms of the device 
Figure 5.3 Schematic shows the integration of microcarriers and gene delivery for large 
scale manufacturing. It can be further improved by incorporating our protocol and 
microfluidic system. Figure was adapted from Molecular Therapy - Methods and Clinical 
Development.161 
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modification and its impact on the ease in investigating the host-pathogen interaction in an 
in vivo-like environment. Several types of research are actively underway to develop gut 
models to support drug discovery and have huge potential to expedite developmental works 
in the pharmaceutical industry.165 These opportunities include target identification and 
validation, drug screening for hit-to-lead and lead optimization, and modelling of 
pharmacokinetic processes that govern drug bioavailability.   
An application in the field of drug discovery that can be benefited by the gut model 
is the screening of the polymer excipient, as well as evaluating the bioavailability of oral 
drugs for different excipient systems. The majority of oral drugs are either hydrophobic or 
crystalline in pure form and thus precipitate out of the aqueous solution. This requires high 
or multiple dosages for effective therapeutic response. One way to overcome this limitation 
is the use of excipient to improve the solubility of the drug in aqueous solutions. The 
solubility often increases due to the complexation of the drug with the excipient molecule 
and the strength of this complexation is critical for its absorption by the GI tract. For the 
drug to be effective, it should be available in free-form for uptake. If the strength of binding 
with the excipient is very strong, this may not be possible. For the screening of the 
excipients, the first step is to evaluate the solubility profile in a gut-simulating fluid. 
However, the bioavailability of drug due to its enhanced solubility can only be tested 
through cell-based in vitro model or animal studies. As discussed in Chapter 5, better in 
vitro models are necessary to reduce the depends on animal model as well as to have a 
better prediction for clinical studies.  
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Permeability assay on the gut-on-a-chip model will be an important tool for the fast 
screening of excipient. The requirement for this model will be more stringent than the one 
we have demonstrated in Chapter 5. The barrier properties of the cell layer for the device 
has to be similar to that of the GI tract. Two ways to characterize the barrier properties are 
transepithelial electrical resistance (TEER) and permeability of inert dye.166 Both methods 
have been employed as gut models,134,167 but require further optimization in terms of their 
adaptability for in-situ validation with culture media. The microfluidic gut model provides 
significant improvement over static trans-well system for investigating the role of fluid 
flow and actual drug dosage on the permeability as well as bioavailability of a drug on the 
blood side.  
In conclusion, these are exciting time for the advancements of microfluidics in the 
field of biotechnology. As chemical engineers, we are uniquely trained in the integration 
of fundamental of engineering principles such as transport phenomena, reaction 
engineering, and polymer physics in microfluidic system for biological and life science 
applications.  This thesis has detailed some of these advancements and envision more 
developmental work in the near future, both academically as well as commercially.  
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